Treponema pallidum subspecies pallidum (T. pallidum) causes syphilis via sexual exposure or via vertical transmission during pregnancy. T. pallidum is renowned for its invasiveness and immune-evasiveness; its clinical manifestations result from local inflammatory responses to replicating spirochaetes and often imitate those of other diseases. The spirochaete has a long latent period during which individuals have no signs or symptoms but can remain infectious. Despite the availability of simple diagnostic tests and the effectiveness of treatment with a single dose of long-acting penicillin, syphilis is re-emerging as a global public health problem, particularly among men who have sex with men (MSM) in high-income and middle-income countries. Syphilis also causes several hundred thousand stillbirths and neonatal deaths every year in developing nations. Although several low-income countries have achieved WHO targets for the elimination of congenital syphilis, an alarming increase in the prevalence of syphilis in HIV-infected MSM serves as a strong reminder of the tenacity of T. pallidum as a pathogen. Strong advocacy and community involvement are needed to ensure that syphilis is given a high priority on the global health agenda. More investment is needed in research on the interaction between HIV and syphilis in MSM as well as into improved diagnostics, a better test of cure, intensified public health measures and, ultimately, a vaccine.


Syphilis is a sexually transmitted infection (STI) that can also be transmitted vertically. It is caused by the spirochaete Treponema pallidum subspecies pallidum (order Spirochaetales) (Fig. 1). Three other organisms within this genus are causes of nonvenereal or endemic treponematoses. T. pallidum subspecies pertenue is the causative agent of yaws, T. pallidum subspecies endemicum causes endemic (nonvenereal) syphilis and T. carateum causes pinta. These pathogens are morphologically and antigenically indistinguishable. However, they can be differentiated by their age at acquisition, principal mode of transmission, clinical manifestations, capacity for invasion of the central nervous system (CNS) and placenta, and genomic sequences, although the accuracy of these differences remains a subject of debate1. Analyses based on the mutation rates of genomic sequences suggest that the causative agents of yaws and venereal syphilis diverged several thousand years ago from a common progenitor originating in Africa2. These estimates argue against the so-called Columbian hypothesis — the notion that shipmates of Christopher Columbus imported a newly evolved spirochaete causing venereal syphilis from the New World into western Europe in the late 15th century3.

Figure 1: Treponema pallidum.

a | Like all spirochaetes, Treponema pallidum consists of a protoplasmic cylinder and cytoplasmic membrane bounded by a thin peptidoglycan sacculus and outer membrane239,240. Usually described as spiral-shaped, T. pallidum is actually a thin planar wave similar to Borrelia burgdorferi, the agent that causes Lyme borreliosis239. The bacterium replicates slowly and poorly tolerates desiccation, elevated temperatures and high oxygen tensions55. b | Periplasmic flagellar filaments, a defining morphological feature of spirochaetes, originate from nanomotors situated at each pole and wind around the cylinder atop the peptidoglycan, overlapping at the middle of the cell. Force exerted by the rigid filaments against the elastic peptidoglycans deforms the sacculus to create the flat-wave morphology of the spirochaete100. Panel b is reproduced with permission from American Society for Microbiology (Ref. 239): Journal of Bacteriology, volume 191, 7566–7580, doi: 10.1128/JB.01031-09. c | Ultrathin section of T. pallidum showing the outer and cytoplasmic membranes and flagellar filaments (endoflagella) within the periplasmic space9. d | Surface rendering of a flagellar motor based on cryo-electron tomograms. Panel d is reproduced with permission from Ref. 240, Elsevier. e | Darkfield micrograph showing the flat-wave morphology of T. pallidum. The arrow and arrowhead indicate segments that are oriented 90° from each other. The different appearances of the helical wave at 90° to the viewer can be explained only by a flat-wave morphology; a corkscrew shape would appear the same from any angle. Panel e is reproduced with permission from American Society for Microbiology (Ref. 239): Journal of Bacteriology, volume 191, 7566–7580, doi: 10.1128/JB.01031-09.

PowerPoint slide

T. pallidum is an obligate human pathogen renowned for its invasiveness and immune-evasiveness47; clinical manifestations result from the local inflammatory response elicited by spirochaetes replicating within tissues810. Infected individuals typically follow a disease course divided into primary, secondary, latent and tertiary stages over a period of ≥10 years. Different guidelines define early latency as starting 1–2 years after exposure. Typically, ‘early syphilis’ refers to infections that can be transmitted sexually (including primary, secondary and early latent infections) and is synonymous with active (infectious) syphilis; the WHO defines ‘early syphilis’ as an infection of <2 years duration11, whereas the guidelines from the United States12 and Europe13 define it as an infection <1 year in duration. These differences in definition can affect the interpretation of results and the prescription of therapeutic regimens used in some circumstances.

Owing to its varied and often subtle manifestations, which can mimic other infections, syphilis has earned the names the Great Imitator and Great Mimicker14. Patients with primary syphilis present with a single ulcer (chancre) or multiple lesions on the genitals or other body sites involved in sexual contact and present regional lymphadenopathy 3 weeks after infection; these are typically painless and resolve spontaneously. Resolution of primary lesions is followed 6–8 weeks later by secondary manifestations, which can include fever, headache and a maculopapular rash on the flank, shoulders, arm, chest or back and that often involves the palms of the hands and soles of the feet. As signs and symptoms subside, patients enter a latent phase, which can last many years. A patient in the first 1–2 years of latency is still considered infectious owing to a 25% risk of secondary syphilis-like relapses15. Historical literature suggests that 15–40% of untreated individuals will develop tertiary syphilis, which can manifest as destructive cardiac or neurological conditions, severe skin or visceral lesions (gummas) or bony involvement9. Recent data suggest that tertiary syphilis is less common today, perhaps owing to the wide use of antibiotics. Numerous case reports and small series suggest that HIV infection increases the risk of neuro-ophthalmological complications in those with syphilis16. Importantly, neurosyphilis is typically described as a late manifestation but can occur in early syphilis. Indeed, T. pallidum can be frequently identified in the cerebral spinal fluid (CSF) of patients with early disease9,15,17. However, the majority of patients with early syphilis who have CSF abnormalities do not demonstrate CNS symptoms and do not require therapy for neurosyphilis12. Symptomatic manifestations of neurosyphilis include chronic meningitis, meningovascular stroke-like syndromes and manifestations common in the neurological forms of tertiary syphilis (namely, tabes dorsalis and general paresis, a progressive dementia mimicking a variety of psychotic syndromes)9. Numerous case reports and small series suggest that HIV infection predisposes individuals with syphilis to neuro-ophthalmological complications16. Cardiovascular syphilis, typically involving the aortic arch and leading to aneurysmal dilatation, usually occurs 10–30 years after the initial infection9.

Sexual transmission of syphilis occurs during the first 1–2 years after infection (that is, during primary, secondary and early latent stages of infection)9. The risk of mother-to-child transmission (MTCT) is highest in primary and secondary stages, followed by the early latent stage. However, transmission risk continues during the first 4 years after exposure, after which the risk of vertical transmission declines over time18. The rate of fetal infection depends on the stage of maternal infection, with 30% of pregnancies resulting in fetal death in utero, stillbirth (late second and third trimester fetal death) or death shortly after delivery1921. Infants born to infected mothers are often preterm, of low birthweight or have clinical signs that mimic neonatal sepsis (that is, poor feeding, lethargy, rash, jaundice, hepatosplenomegaly and anaemia).

Given that T. pallidum has a long generation time of 30–33 hours22, long-acting penicillin preparations (such as benzathine penicillin G) are the preferred therapies for most patients with syphilis. Since the 1940s (when penicillin became widely available), syphilis prevalence has continued to decline in regions able to appropriately test for and treat the infection. However, syphilis outbreaks continue to occur throughout the world. In particular, with declining AIDS-related mortality related to effective HIV treatment over the past two decades, syphilis has re-emerged in urban settings among men who have sex with men (MSM). High-income and middle-income countries have observed rises in syphilis case rates as well as increased neurosyphilis case rates (such as ocular syphilis) and, in some countries, congenital syphilis. In low-income countries where syphilis prevalence has remained high, MTCT of syphilis continues to be the most common cause of STI-related mortality outside HIV23,24, with perinatal deaths owing to untreated syphilis exceeding those due to HIV or malaria25. Following malaria, syphilis is now the second-leading cause of preventable stillbirths worldwide25.

Syphilis should be an ideal disease for elimination as it has no known animal reservoir, can usually be diagnosed with simple and inexpensive tests and can be cured9,16. Nevertheless, syphilis remains a continuing public health challenge globally26. In this Primer, we describe recent discoveries that have improved our understanding of the biological and genetic structure of the pathogen, novel diagnostic tests and testing approaches that can improve disease detection and current, evidence-based management recommendations. We also draw attention to the call for the global elimination of MTCT of syphilis and HIV, as well as recent successes in eliminating syphilis in low-income and middle-income countries (LMICs), particularly through fundamental public health strategies such as ensuring quality antenatal care that includes testing for syphilis early in pregnancy and providing prompt treatment of women and their partners. We also report on the rising numbers of syphilis cases in MSM and ongoing work supporting improved interventions against syphilis in marginalized populations and, ultimately, the development of an effective vaccine.


According to the most recent estimation of the WHO, 17.7 million individuals globally 15–49 years of age had syphilis in 2012, with an estimated 5.6 million new cases every year27 (Fig. 2). The estimated prevalence and incidence of syphilis varies substantially by region or country, with the highest prevalence in Africa and >60% of new cases occurring in LMICs27. The greatest burden of maternal syphilis occurs in Africa, representing >60% of the global estimate23,24.

Figure 2: Incidence of syphilis worldwide.

The WHO estimates of incident cases of syphilis by region in 2012 are shown for the different geographical regions. Data from Ref. 27.

PowerPoint slide

Prevalence and incidence

In LMICs, the heterosexual spread of syphilis has declined in the general population but remains problematic in some high-risk subpopulations, such as female sex workers (FSWs) and their male clients. A recent study of FSWs in Johannesburg, South Africa, showed that 21% of participating women had antibodies suggestive of past or current infection, and 3% had an active (infectious) infection28. Another study of FSWs in 14 zones in Sudan showed a high seroprevalence (median 4.1%), with the highest value (8.9%) in the eastern zone of the country29. A large study of >1,000 FSWs in Kampala, Uganda, showed that 21% were seropositive for syphilis and 10% had an active infection30. Studies in emerging economies, such as China, indicate that syphilis is increasing among ‘mobile men with money’ (Ref. 31). Although syphilis case rates are low in the general population in China, syphilis prevalence is 5% among FSWs and 3% among their male clients31,32. The risk of infection varies among FSWs working in different venues, with the highest prevalence (10%) among street-based FSWs and the lowest prevalence (2%) among venue-based FSWs33.

By contrast, higher-income countries have had declining syphilis prevalence among heterosexual men and women. However, a resurgence of syphilis that disproportionately affects MSM has been noted. Syphilis is associated with high-risk sexual behaviours and infection substantially increases in association with HIV transmission and acquisition. Indeed, the numbers and rates of reported cases of syphilis among MSM in the United States and western Europe have been increasing since 1998 (Ref. 34). In 2015, the case rate for primary and secondary syphilis among MSM (309 per 100,000) in the United States was 221-fold the rate for women (1.4 per 100,000) and 106-fold the rate for heterosexual men (2.9 per 100,000)35. In Canada, the incidence of syphilis was 300-fold greater among MSM positive for HIV than the reported case rate in the general male population36. Syphilis infection has been associated with certain behavioural and other factors, including incarceration, multiple or anonymous sex partners, sexual activity connected with illicit drug use, seeking sex partners on the Internet and other high-risk sexual network dynamics3741. Risk factors for syphilis are frequently overlapping40. Reports of unusual presentations and rapid progression of syphilis in patients with concurrent HIV infection have led to the hypothesis that infection with or treatment for HIV alters the natural history of syphilis42.


Adverse birth outcomes caused by fetal exposure to syphilis are preventable if women are screened for syphilis and treated before the end of the second trimester of pregnancy21. However, MTCT of syphilis caused such a high rate of perinatal and infant mortality that, in 2007, the WHO and partners launched a global initiative to eliminate it as a public health problem4345. At the time of the campaign launch, 1.4 million pregnant women had active syphilis infections, of whom 80% had attended at least one antenatal visit, suggesting missed opportunities for testing and treatment23. At that time, untreated maternal syphilis infections were estimated to have resulted in >500,000 adverse pregnancy outcomes, including >300,000 perinatal deaths (stillbirths and early neonatal deaths).

Syphilis testing and treatment during pregnancy are highly effective and were included in the Lives Saved Tool for effective maternal–child health interventions46. Furthermore, studies have shown that prenatal syphilis screening, testing to support treatment and treatment during pregnancy are highly cost-effective in most countries regardless of disease prevalence or the availability of resources and can even be cost-saving in LMICs with a syphilis prevalence ≥3% in pregnant women4750. In China, where syphilis and HIV prevalence in pregnant women are low but increasing, the integration of prenatal syphilis and HIV screening was shown to be highly cost-effective51.

Since 2007, an increasing number of countries have implemented regional and national initiatives to prevent MTCT of syphilis52, improving guidance documents, using point-of-care (POC) tests as a means of improving access to testing and treatment and integrating behavioural and medical interventions into HIV prevention and control programmes53. By 2012, these efforts had contributed to a reduction in the global number of adverse pregnancy outcomes due to MTCT of syphilis to 350,000, including 210,000 perinatal deaths, and had decreased the rates of maternal and congenital syphilis by 38% and 39%, respectively23,24. In 2015, Cuba became the first country to be validated for having achieved the elimination of MTCT of HIV and syphilis54. Subsequently, Thailand, Belarus and four United Kingdom Overseas Territories (Bermuda, the Cayman Islands, Montserrat and Antigua) were validated for the elimination of MTCT of HIV and syphilis, Moldova was validated for the elimination of MTCT of syphilis and Armenia was validated for the elimination of MTCT of HIV. However, these gains were mostly in Asia and the Americas — the maternal prevalence in Africa has remained largely unchanged23,24.


Although a local inflammatory response elicited by spirochaetes is thought to be the root cause of all clinical manifestations of syphilis9, the mechanisms that cause tissue damage, as well as the host defences that eventually gain a measure of control over the bacterium, are ill-defined. The recalcitrance of T. pallidum to in vitro culture and the consequent inability to harness genetic techniques to delineate its virulence determinants remain the primary obstacles to progress55. Additionally, the fragility and low protein content of its outer membrane have confounded efforts to characterize surface-exposed molecules56,57. Finally, facile murine models to dissect the host response and the components of protective immunity are also lacking58. Outbred rabbits are essential for isolating T. pallidum strains from clinical specimens59 and for routine propagation in the laboratory60. Because rabbits are highly susceptible to T. pallidum infection, develop lesions grossly and histopathologically resembling chancres following intradermal inoculation and generate antibody responses similar to those in humans, the rabbit is the model organism of choice for studying endogenous and exogenous protective immunity61,62. However, the rabbit model poorly recapitulates some clinical and immunological facets of the human disease63. Not surprisingly, even in the post-genomics era, our understanding of the pathogenic mechanisms in syphilis lags well behind that of other common bacterial diseases63.

Molecular features

The morphological features of T. pallidum are described in Fig. 1. Because of its double-membrane structure, the spirochaete is often described as a Gram-negative bacterium. However, this analogy is phylogenetically, biochemically and ultrastructurally inaccurate63,64. The T. pallidum outer membrane lacks lipopolysaccharides65 and has a markedly different phospholipid composition than the outer membranes of typical Gram-negative bacteria66. Although T. pallidum expresses abundant lipoproteins, these molecules reside predominantly below the surface5,63,67. Accordingly, this paucity of surface-exposed pathogen-associated molecular patterns (PAMPs) enables the spirochaete to avoid triggering host innate surveillance mechanisms, facilitating local replication and early dissemination. Its limited surface antigenicity promotes the evasion of adaptive immune responses (that is, antibody recognition), facilitating persistence5,56,68,69. Collectively, these attributes have earned T. pallidum its designation as ‘the stealth pathogen’ (Refs 63,69). Understanding events unfolding at the host–pathogen interface requires a detailed knowledge of the T. pallidum repertoire of surface-exposed proteins. However, characterization of the protein constituents of the outer membrane has been, and continues to be, daunting8,55,57,63.

Lipoproteins. In the 1980s, investigators screened E. coli recombinant libraries with syphilitic sera and murine monoclonal antibodies based upon the unproven (and, as it turned out, immunologically incorrect) assumption that immunoreactive proteins ought to be surface-exposed in T. pallidum57. Biochemical and genetic analyses subsequently revealed that most of the antigens identified by these screens are lipoproteins7072 tethered by their N-terminal lipids to the cytoplasmic membrane (hence, the protein moieties are in the periplasmic space)67,7375. However, convincing evidence now shows that the spirochaete displays small amounts of lipoproteins on its surface that have the potential to enhance infectivity (Fig. 3). For example, TP0751 (also known as pallilysin) is a laminin-binding lipoprotein and zinc-dependent metalloproteinase capable of degrading clots and the extracellular matrix7678. Although expressed by T. pallidum in minute quantities, surface exposure of TP0751 has been demonstrated by knock-in experiments in Borrelia burgdorferi (the spirochaete that causes Lyme borreliosis79) and the cultivatable commensal treponeme Treponema phagedenis80, in opsonophagocytosis assays in T. pallidum77 and, most recently, in the protection of immunized rabbits against the dissemination of spirochaetes following intradermal challenge81. The X-ray structure of TP0751, which demonstrates an unusual lipocalin fold, should inform efforts to clarify its multifunctionality79. Additionally, the lipoprotein Tpp17 (also known as TP0435) has been shown to be at least partially surface-exposed and can function as a cytadhesin82. The structurally characterized lipoprotein TP0453 attaches to the inner leaflet of the outer membrane via its N-terminal lipids and two amphipathic helices within its protein moiety83.

Figure 3: Molecular architecture of the cell envelope of Treponema pallidum.

Shown in the outer membrane are TP0751 (as known as pallilysin)79,81 and Tpp17 (also known as TP0435)82,241, two surface-exposed lipoproteins; TP0453, a lipoprotein attached to the inner leaflet of the outer membrane83; β-barrel assembly machinery A (BamA, also known as TP0326)84,94; a full-length T. pallidum repeat (Tpr) attached by its N-terminal portion to the peptidoglycan93,94; and a generic β-barrel that represents other non-Tpr outer membrane proteins (OMPs) identified by computational mining of the T. pallidum genome112. Substrates and nutrients present in high concentration in the extracellular milieu (such as glucose) traverse the outer membrane through porins, such as TprC. At the cytoplasmic membrane, prototypic ABC-like transporters (such as RfuABCD, a riboflavin transporter) use a periplasmic substrate-binding protein (SBP), usually lipoproteins, and components with transmembrane and ATP-binding domains to bind nutrients that have traversed the outer membrane for transport across the cytoplasmic membrane. The energy coupling factor (ECF)-type ABC transporters use a transmembrane ligand-binding protein in place of a separate periplasmic SBP for binding of ligands (BioMNY is thought to transport biotin)242. Symporter permeases (for example, TP0265) use the chemiosmotic or electrochemical gradient across the cytoplasmic membrane to drive substrate transport243. The tripartite ATP-independent periplasmic (TRAP)-type transporters also use transmembrane electrochemical gradients to drive substrate transport; the periplasmic component protein TatT (also known as TP0956) likely associates with the SBP TatP (also known as TP0957), which binds ligands (perhaps hydrophobic molecules, such as long chain fatty acids), the uptake of which is probably facilitated by the permease TatQ-M (also known as TP0958)244,245. Figure adapted from Ref. 63, Macmillan Publishers Limited.

PowerPoint slide

BamA. With the publication of the T. pallidum genome in 1998 (Ref. 65), only one protein with sequence relatedness to an outer membrane protein of Gram-negative bacteria was identified: β-barrel assembly machinery A (BamA, also known as TP0326)84,85. BamA has a dual domain architecture consisting of a 16-stranded, outer membrane-inserted, C-terminal β-barrel and five tandem polypeptide transport-associated repeats within the periplasm84,85. The opening of the channel is covered by a ‘dome’ comprising three extracellular loops, one of which contains an opsonic target that is sequence-variable among T. pallidum strains85. BamA is the essential central component of the molecular machine that catalyses the insertion of newly exported outer membrane proteins to the outer membrane86.

Tpr proteins. The T. pallidum repeat (Tpr) proteins, a 12-member paralogous family with sequence homology to the major outer sheath protein of the oral commensal Treponema denticola, were also identified in the T. pallidum genomic sequence65. Of these, TprK (TP0897) has received the most attention because of its presumed role in immune evasion by the spirochaete87,88; it has been shown to undergo antigenic variation in seven regions believed to be extracellular loops harbouring B cell epitopes8992. DNA sequence cassettes that correspond to V-region sequences in an area of the T. pallidum chromosome located away from the tprK gene have been proposed to serve as unidirectional donor sites for the generation of variable regions by nonreciprocal gene conversion89. Two other Tpr proteins, TprC and TprI, have met stringent experimental criteria for being classified as rare outer membrane proteins. They form trimeric β-barrels when refolded in vitro, cause large increases in permeability upon insertion into liposomes and are surface-exposed opsonic targets in T. pallidum93,94. Unlike classic porins, for which the entire polypeptide forms a β-barrel, TprC and TprI are bipartite. As with BamA, the C-terminal domain forms the surface-exposed β-barrel, whereas the N-terminal half anchors the barrel to the peptidoglycan sacculus. These results collectively imply that Tprs serve as functional orthologues of Gram-negative porins, using variations in the substrate specificities of their channel-forming β-barrels, probably along with differential expression, to import the nutritional requirements of the spirochaete into the periplasmic space from blood and body fluids95,96. These proteins also furnish a topological template for efforts to understand how antibody responses to Tprs promote bacterial clearance.

Biosynthetic machinery. T. pallidum has evolved to dispense with a vast amount of the biosynthetic machinery found in other bacterial pathogens55,6365. T. pallidum relies on an optimized conventional glycolytic pathway as its primary means for generating ATP. By dispensing with oxidative phosphorylation, the spirochaete has no need for cytochromes and the iron required to synthesize them. Accordingly, the spirochaete maintains a complex, yet parsimonious, assortment of ABC transporters and symporters (totalling 5% of its 1.14 Mb circular genome) to transfer essential molecules from the periplasmic space to the cytosol (Fig. 3). Whereas many pathogens have highly redundant systems for the uptake of transition metals across the cytoplasmic membrane, T. pallidum accomplishes this task with just two ABC transporters (Tro, which imports zinc, manganese and iron, and Znu, which is zinc-specific). A small but powerful arsenal of enzymes neutralizes superoxides and peroxides to fend off host responses to infection. Lastly, the spirochaete possesses novel and surprisingly intricate mechanisms ostensibly to redirect transcription and fine-tune metabolism in response to environmental cues and nutrient flux63.

Transmission and dissemination

Transmission of venereal syphilis occurs during sexual contact with an actively infectious partner; exudate containing as few as ten organisms can transmit the disease8,68. Spirochaetes directly penetrate mucous membranes or enter through abrasions in skin, which is less heavily keratinized in perigenital and perianal areas than skin elsewhere8,68. To establish infection, T. pallidum must adhere to epithelial cells and the extracellular matrix components; in vitro binding studies suggest that fibronectin and laminin are key substrates for these interactions76,9799. Once below the epithelium, organisms multiply locally and begin to disseminate through the lymphatic system and bloodstream. Spirochaetes penetrate the extracellular matrix and intercellular junctions via ‘stop and go’ movements that coordinate adherence with motility and are powered by front-to-back undulating waves generated by flagellar rotation and presumably assisted by the proteolytic activity of TP0751 (Refs 77,100). Ex vivo studies using cultured human umbilical vein endothelial cells (Fig. 4a) suggest that spirochaetes invade tissues using motility to negotiate their way through intercellular junctions: so-called ‘interjunctional’ penetration7,101. The infection rapidly becomes systemic9,16,100. Profuse spirochaetes within the epidermis and superficial dermis in secondary syphilitic lesions (Fig. 4b) enable tiny abrasions created during sexual activity to transmit infection10,102. Penetration of the blood–brain barrier, occurring in as many as 40% of individuals with untreated early syphilis, can cause devastating neurological complications9,16.

Figure 4: Treponema pallidum invasion.

a | Transmission electron micrograph of Treponema pallidum (arrowheads) penetrating the junctions between cultured umbilical vein endothelial cells. ‘Interjunctional invasion’ following attachment to the vascular endothelium is thought to provide T. pallidum access to tissue parenchyma during haematogenous dissemination. Part a is reproduced by permission of Oxford University Press (Ref. 101): Riley, B.S. et al., Virulent Treponema pallidum activates human vascular endothelial cells, The Journal of infectious diseases, 1992, 165, 3, 484–493. b | Immunohistochemical staining (using commercial anti-T. pallidum antibodies) of a secondary syphilitic skin lesion reveals abundant spirochaetes embedded within a mixed cellular inflammatory infiltrate in the papillary dermis. The inflammatory response elicited by spirochaetes replicating in tissues is widely thought to be the cause of clinical manifestations at all stages of syphilis. Reproduced from Ref. 10. c | Fluorescence microscopy images showing that human syphilitic serum (HSS) dramatically enhances opsonophagocytosis of T. pallidum by purified human peripheral blood monocytes compared with part d, which shows normal human serum (NHS). Arrowheads indicate treponemes being degraded within phagolysosomes.

PowerPoint slide

Adaptive immune response and inflammation

Although the paucity of PAMPs in the T. pallidum outer membrane enables the bacterium to replicate locally and undergo repeated bouts of dissemination, pathogen sensing in the host is eventually triggered. The organisms are taken up by dendritic cells103, which then traffic to draining lymph nodes to present cognate treponemal antigens to naive B cells and T cells. The production of opsonic antibodies markedly enhances the uptake and degradation of spirochaetes by phagocytes (Fig. 4c,d), liberating lipopeptides and other PAMPs for binding to Toll-like receptors lining the interior of the phagosome and antigenic peptides for presentation to locally recruited T cells62,104,105. Activated lesional T cells secrete IFNγ, promoting clearance by macrophages but also bolstering the production of tissue-damaging cytokines, such as tumour necrosis factor and IL-6 (Refs 10,106,107). Immunohistochemical analysis has identified CD4+ and CD8+ T cells10,106,108,109, natural killer cells10 and activated macrophages in early syphilitic lesions10,109. Perivascular infiltration of lymphocytes, histiocytes (phagocytic cells in connective tissues) and plasma cells with endothelial cell swelling and proliferation are characteristic histopathological findings in all stages of syphilis and can progress to frank endarteritis obliterans (leading to the occlusion of arteries and severe clinical manifestations, such as the stroke syndromes of meningovascular syphilis)9,110.

Antibody avoidance

T. pallidum is widely regarded as an extracellular bacterium61. Thus, a question of paramount importance is why, unlike ‘classic’ extracellular pathogens, syphilis-causing spirochaetes not only fail to be cleared rapidly but can also replicate and circulate in the midst of a prolific antibody response8,68,69. Immunolabelling, opsonophagocytosis and complement-dependent neutralization assays have shown that T. pallidum populations consist of antibody-binding and nonbinding subpopulations; the minority of organisms that bind antibodies do so in minute amounts and with delayed kinetics10,111114. Accordingly, one can envision a scenario whereby nonbinders replenish the spirochaetes that bind and are cleared63.

Understanding the basis for the heterogeneity of T. pallidum's surface antigenicity is critical to unravelling its strategy for antibody avoidance. The picture emerging from our evolving understanding of the molecular architecture of the spirochaete is multifactorial and probably involves the copious production of antibodies against subsurface lipoprotein ‘decoys’ (Refs 57,110); poor target availability due to low copy numbers of outer membrane proteins and surface-exposed lipoproteins67,77,82,84,93; in the case of bipartite outer membrane proteins, limited production of antibodies against surface-exposed epitopes along with the skewed production of antibodies against periplasmic domains84,93; organism-to-organism variation in the levels of expression of outer membrane proteins and outer surface lipoproteins through a variety of mechanisms, including phase variation82,92,115,116; and, in the case of TprK, antigenic variation as a result of intra-genomic recombination89,92,117. Additionally, the ability of motile spirochaetes to ‘outrun’ infiltrating phagocytes and reach sequestered locations, including the epidermis, could be an under-appreciated aspect of immune evasion10,102. As infection proceeds, the antibody repertoire possibly broadens and intensifies to the point where the antigen-poor surface of the spirochaete is overwhelmed and its capacity for antigenic variation is exhausted, ushering in the asymptomatic period called latency. Once in the latent state, the organism can survive for years in untreated individuals, establishing niduses of inflammation in skin, bones, the thoracic aorta, the posterior uveal tract and the CNS that set the stage for recrudescent disease — collectively referred to as tertiary syphilis. How immune containment mechanisms decline and enable the balance to shift back in favour of the pathogen in tertiary syphilis is unclear9, although a hyper-intense cellular response to the spirochaete is generally believed to be the cause of the highly destructive lesions of tertiary syphilis9.

Congenital infection

Although MTCT of syphilis can occur at the time of delivery, the overwhelming majority of cases are caused by in utero transmission. Studies have shown spirochaetes in placental and umbilical cord samples, supporting the transplacental passage of the organism to the fetus, as early as 9–10 weeks of gestation118. Although fetal syphilis infections were thought to not occur before the second trimester, the fetus can indeed be infected very early in pregnancy but may be unable to mount a characteristic immune response until the development of the embryonic immune system at 18–20 weeks of gestation.

Transmission risk is directly related to the stage of syphilis in the pregnant woman (that is, the extent and duration of fetal exposure to spirochetes). Small case series have found the highest MTCT risk in primary and secondary stages, during which transmission probability may be ≥80%. Systematic reviews assessing women with predominantly asymptomatic infections are consistent in showing that delayed or inadequate treatment results in stillbirth, early neonatal death, prematurity, low birthweight or congenital infection in infants (more than half of syphilis-exposed fetuses); syphilitic stillbirth was the most commonly observed adverse outcome21,45,119.

Diagnosis, screening and prevention

Syphilis has varied and often subtle manifestations that make clinical diagnosis difficult and can lead to many infections being unrecognized. The classically painless lesions of primary syphilis can be missed, especially in hidden sites of exposure such as the cervix or rectum. The rash (Fig. 5) and other symptoms of secondary syphilis can be faint or mistaken for other conditions. A syphilis diagnosis is often based on a suggestive clinical history and supportive laboratory9,16 (that is, serodiagnostic) test results. Serological testing has become the most common means to diagnose syphilis, whether in people with symptoms of syphilis or in those who have no symptoms but are identified through screening. A limitation of all syphilis serological tests is their inability to distinguish between infection with T. pallidum subspecies pallidum and the T. pallidum subspecies that cause (nonvenereal) yaws, pinta or bejel.

Figure 5: Clinical presentation of primary, secondary and congenital syphilis.

a | Primary chancre. b | Primary chancre with rash in secondary syphilis. c | Secondary syphilis in a pregnant woman who has a palmar rash. d | Palmar rash in secondary syphilis. e | 3-month-old baby with congenital syphilis showing hepatosplenomegaly and a desquamating rash. The child also presented with nasal discharge. f | Typical palmar desquamating rash in a baby with congenital syphilis.

PowerPoint slide

Ensuring the accuracy and reliability of syphilis testing is important, especially in nonspecialized laboratories, where most patient samples are tested120. Syphilis-specific quality assurance strategies include the training of technologists on specific techniques as well as implementation of internal quality control systems, test evaluation and interassay standardization of commercially available test kits on a regular basis37,120. It is especially important to provide adequate training and regular external quality assessment or proficiency testing with corrective action to ensure the quality of tests and testing for health care providers who perform rapid tests in clinic-based or outreach settings121124. Because many parts of the world lack laboratory capacity for making an accurate diagnosis, the requirement for laboratory testing has greatly constrained the control of syphilis and the elimination of congenital syphilis. However, the development of inexpensive, rapid tests that can be performed at the POC has greatly increased access to prenatal screening and diagnosis, even in under-resourced and remote settings.

Definitive diagnosis by direct detection

The choice of method for diagnosing syphilis depends on the stage of disease and the clinical presentation125. In patients presenting with primary syphilitic ulcers, condyloma lata (genital lesions of secondary syphilis) or lesions of congenital syphilis, direct detection methods — which include darkfield microscopy, fluorescent antibody staining, immunohistochemistry and PCR — can be used to make a microbiological diagnosis. However, with the exception of PCR, these methods are insensitive and require fresh lesions from which swab or biopsy material can be collected, as well as experienced technologists (Table 1).

Table 1 Direct detection methods for Treponema pallidum

Microscopy had been used for direct detection and diagnosis since 1920 but is now used infrequently. A 2014 survey of national reference and large clinical laboratories in Latin America and the Caribbean showed that only two of 69 participating facilities, of which half were reference laboratories, still performed darkfield or direct fluorescent antibody staining for T. pallidum (DFA-TP)126. The most recent European guidelines recommended against DFA-TP testing in clinical settings, and the reagents are no longer available13. PCR techniques are increasingly used; however, there is as yet no commercially available or internationally approved PCR test for T. pallidum13. Species-specific and subspecies-specific T. pallidum PCR testing is a developing technology that is still primarily available only in research laboratories127,128, although these tests are anticipated to be more widely available in the near future. A systematic review and meta-analysis concluded that T. pallidum PCR testing was more efficient for confirming a diagnosis of syphilis than for excluding a diagnosis in samples from lesions129. Recent research indicates that this technology might be helpful for the diagnosis of neurosyphilis via the detection of T. pallidum DNA in the CSF of patients with syphilis, particularly among individuals infected with HIV130,131.

Diagnosis using serology

Serodiagnostic tests are the only means for screening asymptomatic individuals and are the most commonly used methods to diagnose patients presenting with signs and symptoms suggestive of syphilis. Serodiagnostic tests for syphilis can be broadly categorized into nontreponemal tests (NTTs) and treponemal tests (TTs).

NTTs. NTTs measure immunoglobulins (IgM and IgG) produced in response to lipoidal material released from the bacterium and/or dying host cells. The most commonly used NTTs — the rapid plasma reagin (RPR) test, the toluidine red unheated serum test (TRUST) and the Venereal Disease Research Laboratory (VDRL) test — are flocculation (precipitation) tests that detect antibodies to a suspension of lecithin (including phosphatidylcholine and phosphatidylethanolamine), cholesterol and cardiolipin. NTTs are useful in detecting active syphilis. However, because individuals with an infection do not become positive until 10–15 days after the onset of the primary lesion, 25–30% of primary syphilis cases may be missed132,133 (Fig. 6). Although simple and inexpensive, NTTs must be performed manually on serum, and they rely on a subjective interpretation (Table 2). These tests also require trained laboratory personnel and specialized reagents and equipment and, therefore, do not fulfil the ASSURED (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to those who need them) criteria for tests that can be used at the POC134.

Figure 6: Serological response to primary and secondary syphilis.

Diagnosis of syphilis can be made by measuring a patient's serological response to infection. IgM antibodies against Treponema pallidum proteins are the first to appear, followed a few weeks later by IgG antibodies. Both IgM and IgG antibodies can be measured using treponemal tests such as the T. pallidum haemagglutination assay (TPHA), T. pallidum particle assay (TPPA), fluorescent treponemal antibody absorption assay (FTA-ABS), enzyme immunoassays (EIAs) and chemiluminescence immunoassays (CIAs). IgM and IgG antibodies against proteins that are not specific to T. pallidum (nontreponemal antibodies) can be detected using the rapid plasma reagin (RPR) Venereal Disease Research Laboratory (VDRL) or toluidine red unheated serum (TRUST) tests and usually appear 2–3 weeks after treponemal antibodies are detected. With effective treatment (which is arbitrarily shown here as occurring at 6 months), the nontreponemal antibody levels decline, whereas the treponemal antibodies remain high for many years. In 20% of patients, nontreponemal antibodies persist 6 months after treatment; these individuals are labelled as having a serofast status. Despite repeated treatment, 11% of patients remain serofast187. Here, we show early syphilis (including primary, secondary and early latent infections; infectious syphilis) and late syphilis (including late latent and tertiary infections) as being ≤1 year in duration and >1 year in duration, respectively, in line with US and European guidelines. However, the WHO guidelines place this demarcation at 2 years. Beyond primary and secondary syphilis, the pattern of serological response over time is less well defined and is accordingly not shown.

PowerPoint slide

Table 2 Serological tests for Treponema pallidum

Without treatment, titres peak at 1–2 years after infection and remain positive even in late disease (usually at a low titre). After treatment, titres generally decline and in most immunocompetent individuals become nonreactive within 6 months. However, up to 20% of individuals infected with syphilis show persistently reactive (albeit low-titre) NTT results even after treatment, possibly related to a less-robust pro-inflammatory immune response135. These patients are labelled as having a serofast status, which is observed more commonly with treatment for late latent than for early syphilis37,136. Biological false-positive results can occur in 2–5% of the population, regardless of the NTT test used, although the proportion is difficult to estimate with certainty because it is influenced by the population studied137. These low-titre reactions might be of limited duration if related to acute factors (such as febrile illness, immunization or pregnancy) or longer duration if related to chronic conditions (such as autoimmune diseases, hepatitis C infection or leprosy)136,138. By contrast, false-negative results can occur in sera with very high titres (such as sera from patients with secondary syphilis) that are not diluted before testing, a phenomenon known as a prozone effect. Pre-dilution of sera re-establishes the concentration needed for optimal antibody–antigen interaction and avoids this problem.

TTs. In contrast to NTTs, TTs detect antibodies directed against T. pallidum proteins and are theoretically highly specific. However, as most individuals infected with syphilis develop treponemal antibodies that persist throughout life, TTs cannot be used to distinguish an active from a past or previously treated infection and are not useful in evaluating treatment effectiveness. TTs are used as confirmatory assays following a positive NTT result.

TT results become positive 6–14 days after the primary chancre appears (5 weeks after infection) and, therefore, may be useful to detect early syphilis missed by NTT testing. These tests are usually laboratory-based and include the fluorescent treponemal antibody absorbed (FTA-ABS) test, the microhaemagglutination assay for antibodies to T. pallidum (MHA-TP), the T. pallidum passive particle agglutination (TPPA) and T. pallidum haemagglutination (TPHA) assays (Table 2). These tests also require trained personnel in a laboratory setting, are more expensive and technically complex than NTTs and involve specialized reagents and equipment. For these reasons, in the developing world, laboratory-based TTs are not widely available in primary care settings, hence limiting their utility as assays for confirming NTT results.

In recent years, TTs using recombinant T. pallidum antigens in enzyme and chemiluminescence immunoassays (EIA and CIA, respectively) have been commercialized. These assays are useful for large-scale screening as they are automated or semi-automated and, because they are read spectrophotometrically, are not subjective13,139142. In higher-income countries, many health care institutions depend on high-throughput screening and have adopted ‘reverse’ algorithms that screen with an automated treponemal EIA or CIA and confirm results with an NTT rather than the opposite, traditional approach (Fig. 7). Few studies as yet have addressed the accuracy of these ‘reverse testing’ algorithms40,143. The traditional and reverse approaches should theoretically produce the same result. However, the reverse algorithm results in the detection of patients with early syphilis (TT-positive, NTT-negative) who would not be detected by the conventional approach144. As this pattern of serological reactivity occurs in very early primary syphilis, in previously treated disease and late infection, considerable attention should be given to a thorough physical examination of the patient and assessment of previous history and recent sexual risk factors before initiating any treatment and partner notification activities.

Figure 7: Screening algorithms for syphilis.

a | The traditional algorithm begins with a qualitative nontreponemal test (NTT) that is confirmed with a treponemal test (TT). This algorithm has a high positive predictive value when both tests are reactive, although early primary and previously treated infections can be missed owing to the lower sensitivity of NTTs136. Importantly, this algorithm is less costly than reverse screening algorithms and does not require highly specialized laboratory equipment, but it is limited by the subjective interpretation of the technologist. Additionally, false-negative NTT results can arise from the prozone effect (when there is an excess of antibody). Finally, because the traditional algorithm is not always followed by a confirmatory TT, previously treated, early untreated and late latent patients can be missed, and biologically false-positive patients can be overtreated. b | The reverse screening algorithm uses a TT with recombinant T. pallidum antigens in enzyme immunoassay (EIA) or chemiluminescence immunoassay (CIA) formats that, when reactive, is followed by an NTT. This approach is associated with higher initial setup costs and ongoing operational costs than the traditional algorithm, but the algorithm permits treatment of 99% of patients with syphilis, which is higher than the percentage treated on the basis of the traditional algorithm in a low-prevalence setting246. However, this approach is at the expense of serodiagnosis in patients without risk factors and, therefore, who are unlikely to have syphilis, leading to potential overtreatment and any psychosocial consequences associated with a false positive result. Additionally, because TTs are not flocculation assays, false-negative test results due to the prozone effect do not occur. However, in high-risk populations, screening with a TT can result in a high rate of positive results due to previously treated infections, leading to an increase in the clinician workload needed to review cases and determine appropriate management. Some guidelines recommend further evaluation of reactive TT results with a quantitative NTT and, if results of the latter are nonreactive, a second (different) TT to help resolve the discordant results143,247,248. The European Centre for Disease Prevention and Control uses a variation of this approach: a reactive TT immunoassay is followed by a second (different) TT of any kind (that is, not followed by an NTT)249. Ideally, a positive TT result should be supplemented by another TT or an NTT. However, in most developing countries, particularly given the serious consequences of syphilis during pregnancy, treatment is recommended for a patient with a positive TT result. RPR, rapid plasma reagin test; TPHA, T. pallidum haemagglutination assay; TPPA, T. pallidum particle assay; VDRL, Venereal Disease Research Laboratory test.

PowerPoint slide

Rapid tests. Rapid POC TTs are a recent technology that enable onsite screening and treatment and are particularly useful in settings with limited laboratory capacity. Rapid syphilis tests use a finger-prick whole blood sample and are typically immuno-chromatographic strip-based TT assays using components that can be stored at room temperature, require no equipment and minimal training and give a result in <20 minutes145 (Table 2). Various rapid tests have been evaluated in a range of clinical and community settings and shown to fulfil the ASSURED criteria134,146154. Like other TTs, most POC diagnostics have the limitation of being unable to distinguish between recent and previously treated syphilis infections and, therefore, could lead to overtreatment. Ideally, patients who test positive to a POC TT would be further evaluated with an NTT to support management decisions; however, this is often not possible in settings with limited laboratory capacity as is the case in many antenatal care clinics and outreach programmes for high-risk populations. Rapid POC tests play an important part when delayed diagnosis is problematic, such as in pregnant women in whom delayed or no treatment poses substantial risks to the fetus that far outweigh the risks of overtreatment for the mother45,155. In nonpregnant individuals who test positive, the recommendations are treatment for those who have no prior history of treatment and referral to have an NTT for those with a prior history11.

At least one test has been developed that enables the simultaneous detection of nontreponemal and treponemal antibodies in a single POC device156158. Additionally, rapid, dual syphilis and HIV tests are available to screen for HIV and treponemal antibodies using a single lateral-flow immuno-chromatographic strip. These tests are increasingly important tools for the global elimination of MTCT of HIV and syphilis in settings in which laboratory capacity is limited159.

Tests useful in special situations

Neurosyphilis. The diagnosis of neurosyphilis is challenging. The CSF is frequently abnormal in patients with neurosyphilis, with both pleocytosis (lymphocyte accumulation) and an increased protein concentration. The VDRL assay performed on CSF is considered the gold standard for specificity but is recognized to have limited sensitivity160,161. Other CSF tests, including serological assays, such as the RPR162, FTA-ABS163 and TPHA tests164, and molecular assays, such as PCR165, have all been assessed and show differences in their specificity and sensitivity for the diagnosis of neurosyphilis. Difficulties in the interpretation of CSF pleocytosis in individuals co-infected with HIV and syphilis make it challenging to evaluate the relationship between the two diseases. CSF pleocytosis occurs in individuals with either infection alone37,165; thus, discerning the cause of pleocytosis in individuals with co-infections is not always possible.

Congenital syphilis. Diagnosing congenital syphilis in exposed, asymptomatic infants is another area of testing that can be improved. Because maternal nontreponemal and treponemal IgG antibodies can be transferred from mother to child, treponemal testing of infant serum is difficult to interpret and is not recommended37. An infant with a reactive RPR or VDRL serum titre that is at least fourfold that of the mother is highly suggestive of congenital syphilis, but its absence does not exclude a diagnosis. A clinical examination, reactive infant CSF VDRL assay results, abnormal complete blood count or liver function test results or suggestive long-bone radiographs (that, for example, show retarded ossification or dislocation of epiphyses and radiolucencies (low-density areas)) can support a diagnosis of congenital syphilis. Use of IgM immunoblots is controversial due to the limited availability of tests and inconclusive data thus far on their sensitivity; their use in diagnosing congenital syphilis is recommended in some guidelines11,13 but not others37. Maternal syphilis infection is highly correlated with fetal loss; thus, the evaluation of a stillborn infant should include an evaluation of maternal test results for syphilis11.


The wide availability of effective treatments and resulting decline in syphilis prevalence has led to a low yield of screening in low-prevalence settings; thus, screening in low-risk adults (for example, premarital adults or those admitted to hospital) has been abandoned in most places. However, systematic reviews provide convincing evidence in favour of syphilis screening for pregnant women13,166, adults and adolescents at increased risk of infection13,40 and individuals donating blood, blood products or solid organs13,167169. Several countries also recommend syphilis testing in people with unexplained sudden visual loss, deafness or meningitis as these may be manifestations of early neurosyphilis13,37.

Prenatal screening. Syphilis screening is universally recommended for pregnant women, regardless of previous exposure, because of the high risk of MTCT during pregnancy and the availability of a highly effective preventive intervention against adverse pregnancy outcomes11,37,41,46. Global normative authorities and most national guidelines recommend syphilis screening at the first prenatal visit, ideally during the first trimester11,37,41,170. Some countries recommend that women at high risk have repeat screening in the third trimester and again at delivery to identify new infections37. Women should be tested during each pregnancy, even if they tested negative in a previous pregnancy. When access to prenatal care is not optimal or laboratory capacity is limited, rapid tests have been shown to be beneficial in detecting and treating syphilis in pregnant women148. Guidelines recommend that after delivery, neonates should not be discharged from the health facility unless the serological status of the mother had been determined at least once during pregnancy and preferably again at delivery11,37.

The importance of universal syphilis screening in pregnancy to prevent perinatal and infant morbidity and mortality is highlighted in the current WHO global initiative to eliminate congenital syphilis43,44 and is justified by the continuing high global burden of congenital syphilis, availability of an effective and affordable preventive intervention and wider availability of low cost rapid POC tests that can be used when laboratory capacity is lacking23,43,44,46,145. A systematic review of studies (most of which were conducted in low-income countries) reporting on antenatal programmes initiating or expanding syphilis screening, compared with various local control conditions, found that enhanced screening reduced syphilis-associated adverse birth outcomes by >50%171. Integration of syphilis testing with other prenatal interventions, including HIV testing, has been shown to be cost-effective across settings, even when syphilis prevalence is low4851. Strategies that enhance screening coverage, such as increased use of rapid POC testing and integrating syphilis and HIV screening, will further support the global elimination of congenital syphilis145,172174.

Screening at-risk populations. Increased risks of infection can be related to personal or partner behaviours leading to syphilis infection or living in a community with a high syphilis prevalence37,40. In many countries, syphilis testing is recommended for all attendees at STI or sexual health centres and as part of integrated services targeted to high-risk groups (such as HIV testing centres or drug treatment centres)13,37. The optimal screening interval for individuals at an increased risk of infection is not well established; however, some guidelines suggest that MSM or people with HIV show a greater benefit from more frequent screening than others at risk of syphilis infection (for example, testing every 3 months rather than a single annual screening)37,40,175,176.

At-risk communities are often marginalized from care and experience discrimination and stigma when using traditional STI services177. Innovations in promoting the uptake of testing and developing user-friendly services are important in the control of syphilis in these communities to reduce transmission. Social entrepreneurship and crowdsourcing approaches have been shown as innovative approaches to improve HIV and syphilis testing coverage rates and accelerate linkage to care, two fundamental elements within the cascade of STI service delivery178,179. Studies evaluating other interventions, such as pre-exposure prophylaxis for syphilis, are also underway180. One future option might be to administer pre-exposure prophylaxis simultaneously for syphilis and HIV181.

Blood-bank screening. Although syphilis was among the first identified infectious risks for blood donation and syphilis transmission through blood has been documented182184, reports of transfusion-transmitted syphilis have become exceedingly rare over the past 60 years as more countries adopt donor selection processes, universal serological screening of donors and the use of refrigerated products rather than fresh blood components183,185. The survival of T. pallidum in different blood components has been shown to vary according to storage conditions, with fresh blood or blood components stored for <5 days being more infectious than blood stored for longer periods183. Screening of blood, blood components and solid organs for syphilis remains a recommendation in many countries13,169. Occasional cases of transfusion-transmitted syphilis are still reported in settings with high syphilis prevalence, particularly with the transfusion of fresh blood167.


There is as yet no vaccine against syphilis; the most effective mode of prevention is prompt treatment to avoid continued sexual transmission or MTCT, and the treatment of all sex partners to avoid reinfection. Other prevention modalities against the sexual transmission of syphilis are latex condom use, male circumcision and avoiding sex with infected partners37. Treating exposed sex partners is important to avoid reinfection37.


Important factors in managing syphilis are early detection, prompt treatment with an effective antibiotic regimen and treating sex partners of a person with infectious syphilis (primary, secondary or early latent infections). The WHO guidelines11 (Box 1) and European guidelines13 for the management of early syphilis in adults are the same. The US Centers for Disease Control and Prevention (CDC) guidelines do not suggest procaine penicillin as a treatment but are otherwise identical12. Patients with late syphilis are no longer infectious. Thus, the objective of treatment is to prevent complications in persons who are asymptomatic (that is, those who have late latent syphilis) or arrest disease development if the patient has manifestations of tertiary disease. Treating late syphilis requires longer courses of antimicrobial therapy than treating early syphilis.


Penicillin has been the mainstay of treatment for syphilis since it first became widely available in the late 1940s. Although its efficacy was never demonstrated in a randomized controlled trial, it was clearly far superior to all previous treatments, and T. pallidum resistance to penicillin has never been reported. As T. pallidum divides slower than most bacteria, it is necessary to maintain penicillin levels in the blood above the minimum inhibitory concentration for ≥10 days; this can be achieved by giving a single intramuscular injection of long-acting benzathine penicillin G (which benefits from not requiring patient adherence to a long-term drug regimen). The first-line treatments for early syphilis recommended by the CDC and European (authored by the International Union Against Sexually Transmitted Infections) guidelines are very similar12,13, as are recommendations for treating exposed sex partners. Patients with late syphilis, or with syphilis of unknown duration, should receive longer courses of treatment (Box 1). Those with symptoms suggestive of neurosyphilis or ocular involvement should undergo lumbar puncture to confirm or rule out the presence of neurosyphilis, which requires more-intensive treatment. However, CDC and European guidelines define latent syphilis as occurring beginning at 1 year after infection, whereas the WHO defines latent syphilis to occur beginning at 2 years, resulting in some differences in management; that is, a longer treatment duration is recommended for some patients in the United States and Europe.

Given that confirmation or exclusion of the presence of viable T. pallidum after treatment is not possible, treatment efficacy is measured indirectly using serology. Being cured is usually defined as reversion to a negative serostatus or a fourfold reduction in the titre from an NTT. However, as noted earlier, a minority of patients remain seropositive, with a less than fourfold reduction in their NTT titre, in spite of almost certainly having been cured and with no evidence of progressive disease — the so-called serofast state186. The management of these patients depends on taking a careful sexual history to exclude the possibility of reinfection, which can be challenging as patients may not recognize new infections. The serofast state more commonly occurs in patients with late syphilis and low NTT titres and in patients positive for HIV who are not on antiretroviral treatment187. Because few data are available on long-term clinical outcomes in serofast patients, CDC guidelines recommend continuing clinical follow-up and retreatment if follow-up cannot be ensured12.

Second-line treatments

Patients who are allergic to penicillin should be treated with doxycycline or ceftriaxone (although an allergy to cephalosporins is more common in those who are allergic to penicillin) with repeat NTT serology as a follow-up. Doxycycline is contraindicated during pregnancy. Two treatment trials of early syphilis in Africa showed that a single oral dose of azithromycin was equivalent to treatment with benzathine penicillin G (Refs 188,189). Unfortunately, strains of T. pallidum with a mutation that confers resistance to azithromycin and other macrolide antibiotics are common in the United States, Europe, China and Australia190194. A study of HIV-positive patients with syphilis showed that administering azithromycin to prevent opportunistic infections led to better serological outcomes195. The WHO recommends the use of azithromycin for the treatment of syphilis only in settings where the prevalence of macrolide-resistant T. pallidum is known to be very low.

HIV co-infection

In patients with early syphilis, an increased cell count and protein concentration are found more frequently in the CSF of patients with an HIV infection than in patients without an HIV infection, and there is some evidence that early symptomatic neurosyphilis is more common in patients positive for HIV196,197. As single-dose benzathine penicillin G treatment does not reliably lead to treponemicidal levels in the CSF, some experts have suggested that HIV co-infected patients with early syphilis should receive enhanced treatment198. However, a randomized controlled trial (n = 541) showed no significant difference in clinical outcomes between patients receiving a standard or enhanced treatment15. Notably, the 101 patients infected with HIV enrolled in the trial responded less well serologically, but due to loss at follow-up, the study was underpowered to detect a twofold difference in the standard versus enhanced treatment in patients co-infected with HIV. Furthermore, a large (n = 573) prospective observational study in Taiwan found no difference between single-dose benzathine penicillin G and enhanced treatments in a per-protocol analysis199. However, using a last-observed-carried-forward analysis to account for missing data, the authors concluded that 67.1% of those who received one dose responded serologically compared with the 74.8% response rate in those who received the enhanced treatment, a statistically significant difference (P = 0.044)199. Finally, a retrospective study (n = 478) showed no difference in serological response rates at 13 months between those receiving a single-dose of benzathine penicillin G or enhanced treatment200. Given the inconclusive results of these studies, many clinicians continue to offer enhanced therapy to patients with early syphilis and HIV co-infection.

Treatment during pregnancy

Adverse pregnancy outcomes are common in women with syphilis45,119. A study in Tanzania found that of women with latent syphilis who had RPR titres ≥1:8, 25% delivered a stillborn infant, and 33% delivered a live but preterm infant21. A second study showed that adverse pregnancy outcomes due to syphilis can be prevented with a single dose of benzathine penicillin G given before 28 weeks of gestation201 and that, in this setting in which 5–6% of pregnant women had syphilis, this was one of the most cost-effective interventions available in terms of cost per disability-adjusted life years saved202.

Penicillin is the only antibiotic known to be effective in treating syphilis during pregnancy and preventing adverse birth outcomes. Given that doxycycline is contraindicated during pregnancy, and macrolides such as azithromycin and erythromycin do not cross the placenta effectively, there are few alternatives to penicillin for the treatment of pregnant women with syphilis who are allergic to penicillin. The CDC recommends desensitization for those who are allergic to penicillin12.

Congenital syphilis

The WHO recommends that infants with suspected congenital syphilis, including infants who are born to mothers who are seropositive for syphilis and not treated with penicillin >30 days before delivery, should be treated with aqueous benzyl penicillin or procaine penicillin (Box 1). All infants exposed to syphilis, including infants without signs or symptoms at birth, should be followed closely, ideally with NTT titres. Titres should decline by 3 months of age and be nonreactive by 6 months12. TTs are not useful in infants due to persistent maternal antibodies.

Neurosyphilis and ocular syphilis

Involvement of the CNS can occur during any stage of syphilis, but there is no evidence supporting a need to deviate from recommended syphilis regimens without the presence of clinical neurological findings (such as ophthalmic or auditory symptoms, cranial nerve palsies, cognitive dysfunction, motor or sensory deficits or signs of meningitis or stroke)203. With symptoms and tests indicating neurosyphilis, or any suggestion of ocular syphilis regardless of CSF testing, more-intensive treatment is recommended. For example, the CDC recommends that adults with neurosyphilis or ocular syphilis should be treated with high-dose intravenous aqueous crystalline penicillin, or intramuscular procaine penicillin plus probenecid, for 10–14 days204.

Quality of life

Historical reports dating from the 15th century indicate that syphilis was perceived as a dangerous infection and a source of public alarm via fear of contagion and dread of its manifestations, as well as anxiety around its highly toxic ‘cures’ (heavy metal therapy with mercury, arsenic or bismuth)205207. Case reports through the 19th century, as well as modern re-evaluations of skeletal remains, support the fact that the disease could cause severe physical stigmata, with individuals having disfiguring rashes, nonhealing ulcerations, painful bony lesions that often involved destruction of the nose and palate, visceral involvement, dementia and other incapacitating neurological complications and early death208. Stigmatization associated with syphilis was also evident, with symptomatic patients quarantined to specialized hospitals, and affected people hiding their symptoms, perhaps fearing societal shunning or the dubiously effective treatment regimens even more than they feared the disease209. Reductions in syphilis prevalence were documented after the introduction of penicillin210, and since that time, the most virulent manifestations of the disease have almost vanished; today it is rare to find a patient with tertiary disease211. Nevertheless, continuing reports emphasize that complications of late syphilis, particularly those involving the eyes, CNS and cardiovascular system, can cause lifelong disability and even death9. For example, the number of cases of ocular syphilis has increased with rising syphilis incidence in many communities212, with delayed treatment associated with permanently diminished visual acuity213. Thus, caregivers must be cognizant of the need to screen at-risk patients for latent infection and administer therapy if previous treatment has not been documented.

Few modern studies have addressed quality of life in men and women with syphilis, whether in social, psychological or economic contexts. One study (n = 250) showed only a minor effect on patient-reported quality of life at time of treatment and essentially no effect 1 month after treatment214. The currently high case rates of syphilis infection and reinfection among MSM in urban centres throughout the world might lend support to the notion that syphilis in the modern era poses a limited impact on quality of life as long as it is detected and treated. However, partner notification studies suggest that STI diagnoses can lead to substantial social stigma, intense embarrassment and fear of retaliation, domestic violence or loss of relationships177. Public health experts have posited that syphilis is the source of more stigma than other STI diagnoses, although this is difficult to measure with certainty because STI programmes tend to focus contact tracing efforts more strongly on syphilis than on other curable STIs owing to its serious consequences215. In one study measuring the level of shame associated with several stigmatizing skin diseases, patients assigned the greatest shame to syphilis — more than to HIV/AIDS, other STIs or several disfiguring skin conditions216.

Untreated maternal syphilis results in severe adverse perinatal outcomes, most prominently stillbirth, in at least half of affected pregnant women45. Although MTCT of syphilis is clearly linked to a lack of prenatal care, WHO data indicate that globally, whether in wealthy or poor nations, most adverse pregnancy outcomes caused by maternal syphilis are in women who attended prenatal care but were not adequately tested or treated24. This suggests that other factors, such as ineffective health systems, gender inequality, lack of political will to support quality STI and reproductive health services or other structural influences associated with a lack of screening might be at play217. Increasing research supports the conclusion that, as for infant loss, a stillbirth can lead to poor mental and other health outcomes for both parents and the wider family, even extending to health care providers. For example, experiencing a stillbirth has been linked to ‘unspoken grief’ and a variety of psychosocial consequences such as depression, blame, shame, social isolation, problems in future pregnancies and relationship dissolution218220. In Haiti, pregnancy loss associated with syphilis is so common (maternal prevalence of 6%) that a myth about a werewolf sucking the blood out of the unborn fetus has developed to help women with their loss and suffering221. Economic research suggests that a stillbirth results in substantial direct and indirect costs and can sometimes require more resources than a livebirth219.


With syphilis continuing to be the leading cause of preventable stillbirths in the developing world and re-emerging as a public health threat in developed nations, particularly in MSM co-infected with HIV, the demand for improved diagnostics, prevention strategies and treatments is growing. Here, we describe the most pressing issues and propose a call to action (Box 2).

Elimination of MTCT of syphilis

The WHO campaign to eradicate yaws, which treated >50 million people with penicillin and reduced the number of cases by ≥95% worldwide between 1952 and 1964, was ultimately unsuccessful. What can we learn from this heroic failure? The yaws eradication campaign was based on clinical examination and serological testing to determine prevalence by community and on mass treatment or selective mass treatment (patients and contacts) of communities with penicillin depending on prevalence. Unfortunately, as the prevalence of yaws fell, it was no longer perceived as an important public health problem worthy of an expensive vertical programme; resources were diverted to other programmes, yaws was forgotten, and it re-emerged222. To some extent the same is true of syphilis; once penicillin became available, its incidence and prevalence declined in many parts of the world, and it was no longer seen as a public health priority. Although screening of all pregnant women for syphilis has continued to be recommended in most countries, coverage has been low in many regions; for example, WHO estimates that approximately 50% of antenatal clinic attendees in Africa are not currently screened for syphilis24. This low coverage has resulted in a high burden of entirely preventable stillbirths and neonatal deaths23. Exacerbating this situation, the WHO has received reports of depleted stocks and shortages of injectable benzathine penicillin G in multiple countries, many with a high burden of maternal and congenital syphilis. In collaboration with international partners, the WHO has spearheaded an initiative to assess the global supply, current and projected demand and production capacity for benzathine penicillin G (Ref. 223).

Strong advocacy will be needed to ensure that the control and elimination of syphilis is given a high priority on the global health agenda. Policy makers and funders need to be made aware that syphilis is a leading cause of preventable stillbirths and neonatal death, that these deaths can be prevented with a single dose of penicillin given to the mother before 28 weeks of gestation and that this is one of the most cost-effective health interventions available51,202. Perhaps with this awareness and political will, syphilis MTCT elimination programmes, which have failed to progress in the past 10 years224, will witness the same success achieved in the MTCT of HIV programmes in Africa. Other developments are occurring that are forging change. For example, the availability of POC tests has led to increased coverage of antenatal screening and treatment for syphilis in many settings148, and the WHO campaign for the elimination of MTCT of HIV and syphilis has increased the visibility of syphilis on the global health agenda. In 2014, the WHO target for the elimination of MTCT of syphilis was ≤50 cases of congenital syphilis per 100,000 live births. The targeted processes are antenatal care coverage (at least one visit) of ≥95% of pregnant women, syphilis testing coverage for ≥95% of pregnant women and treatment of ≥95% of pregnant women seropositive for syphilis225. Additionally, the WHO has conducted a systematic review of the performance of rapid, dual HIV and syphilis tests and issued an information note on testing algorithms for dual HIV and syphilis tests226.

The huge reduction in the number of infants positive for HIV in Africa in recent years, a more difficult undertaking than reducing MTCT of syphilis, is proof of concept that congenital syphilis elimination is achievable. Given that Cuba, Thailand, Belarus, Moldova and Armenia have eliminated MTCT of HIV, syphilis or both, elimination can be achieved with political will and a well-organized health care system. Indeed, inclusion of syphilis and HIV screening with tests for anaemia, diabetes and pre-eclampsia as a package of essential diagnostics for prenatal care should be implemented as a minimum standard to ensure safe and healthy pregnancies worldwide.

The use of POC testing has greatly increased access to screening for pregnant women and has the potential to increase access to screening for high-risk groups such as MSM and FSWs through outreach programmes. However, the quality of testing must be assured given that these tests are conducted outside the laboratory. Strategies to ensure the reliability of POC tests include the use of electronic readers227 and microfluidic assays powered by smart phones228 for real-time monitoring of progress229 and the routine provision of proficiency testing panels121,122. For example, one study in the Amazon region of Brazil showed that proficiency panels consisting of dried serum tubes that were assessed by each health care worker could be used to monitor the performance of health care workers in remote settings123.

HIV and syphilis co-infection in MSM

In developed countries, the incidence of syphilis in MSM is several hundred times higher than in the general population. Furthermore, the incidence continues to increase as condom use has fallen with increasing use of pre-exposure prophylactic antiretroviral medications for HIV42,230. Indeed, with wider HIV treatment coverage in recent years and HIV no longer considered a ‘death sentence’, safe sex practices have declined and risk-taking behaviours have increased231. However, the alarming increase in the incidence of syphilis, compared with that of other STIs, in HIV-infected MSM cannot be explained by behavioural factors alone. The frequent co-infection of HIV and syphilis in MSM in many countries has led researchers and policy makers to consider the hypothesis that treatment for HIV may be a double-edged sword that contributes to increased susceptibility to syphilis through impairment of the innate or acquired immunity to T. pallidum42,232.

Accordingly, research is urgently needed to understand the underlying causes of this twin epidemic. The involvement of the MSM community is critical in the design and implementation of innovative approaches to promote the uptake of testing and linkage to care, particularly as this community is still stigmatized and marginalized from care in many societies. Although self-testing for HIV and hepatitis C virus infection is now possible using highly sensitive and specific oral tests that are commercially available, syphilis does not elicit sufficient antibody levels for an oral test. Thus, implementation science is needed to integrate and optimize the delivery of a package of HIV, syphilis, hepatitis and other STI screening and treatment strategies and partner notification systems for MSM in different cultural, socioeconomic and political settings.

Better diagnostic tests

Research is needed to identify biomarkers that can more accurately distinguish between past, treated syphilis infections and active infections requiring treatment, can identify patients who have become reinfected and can provide a test of cure. Using current serological tools, a high proportion of patients have been shown to remain serofast after treatment in some settings, and the optimal management of these individuals is uncertain. Additionally, more-accurate diagnostic tests are needed to confirm the diagnosis of congenital syphilis, as serological tests based on IgG antibodies cannot distinguish between infected infants and those with passively acquired maternal antibodies. IgM tests can be highly sensitive in symptomatic infants but have suboptimal sensitivity in infants who are infected but not symptomatic at birth12.

The diagnosis of neurosyphilis also remains a challenge, particularly in patients co-infected with HIV, in whom an increased CSF protein concentration or cell count does not necessarily indicate that the patient has neurosyphilis. Promisingly, a rapid POC test has been adapted for the diagnosis of neurosyphilis using CSF233; the performance of this test is better in cell-free specimens, requiring the use of a centrifuge. Another promising assay might be the measurement of macrophage migration factor (MIF); measurement of CSF levels of MIF alone was shown to have a sensitivity of 74.42% and a specificity of 67.74% for the diagnosis of neurosyphilis in one study (n = 43)234. By integrating all CSF parameters (pleocytosis, increased protein concentrations and MIF), the sensitivity and specificity would be improved. Additionally, assays of B cell attractant chemokine CXCL13 in the CSF could be used to distinguish the pleocytosis caused by HIV from that caused by neurosyphilis in patients infected with HIV235.

Better use of existing drugs

With the use of penicillin, many countries still struggle with the fear of injections on the part of patients and the management of anaphylactic shock on the part of the health care providers. Oral regimens that are safe for use during pregnancy and effective in preventing the transmission of syphilis to the fetus are urgently needed. Furthermore, macrolide resistance is correlated with treatment failure in patients with primary syphilis191, lending further urgency to the need to find alternative oral therapies. Incentives for a drug discovery programme for syphilis need to be established and, in the meantime, evaluation of existing drug combinations might be useful as alternatives to reduce the threat of developing resistance.

Vaccine development

Human-challenge studies have shown that people with late latent syphilis are resistant to symptomatic reinfection with heterologous strains of T. pallidum, and protective immunity has been induced in rabbits by repeated inoculation with γ-irradiated T. pallidum236,237. Accordingly, it should be possible to develop protective vaccines. However, research on virulence determinants of T. pallidum and our understanding of protective immunity against T. pallidum have been hindered by our inability to culture the bacteria in vitro. Genome sequencing of T. pallidum directly from clinical samples is now possible, which can overcome this limitation92,238. This advance should enable the understanding of strain variation on a global scale and help to identify outer membrane proteins and other surface antigens as possible vaccine candidates81. A recent study showed that the immunization of rabbits with the lipoprotein TP0751 prevented the dissemination of T. pallidum and, hence, has become a promising vaccine candidate81. Integrating potential vaccine targets with diagnostic targets in discovery programmes also holds promise in accelerating progress towards the development of improved tools for the control, prevention and, ultimately, elimination of this disease.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

How to cite this Primer

Peeling, R. W. et al. Syphilis. Nat. Rev. Dis. Primers 3, 17073 (2017).


  1. 1

    Giacani, L. & Lukehart, S. A. The endemic treponematoses. Clin. Microbiol. Rev. 27, 89–115 (2014).

    Google Scholar 

  2. 2

    Smajs, D., Norris, S. J. & Weinstock, G. M. Genetic diversity in Treponema pallidum: implications for pathogenesis, evolution and molecular diagnostics of syphilis and yaws. Infect. Genet. Evol. 12, 191–202 (2012).

    Google Scholar 

  3. 3

    de Melo, F. L., de Mello, J. C. M., Fraga, A. M., Nunes, K. & Eggers, S. Syphilis at the crossroad of phylogenetics and paleopathology. PLoS Negl. Trop. Dis. 4, e575 (2010).

    Google Scholar 

  4. 4

    Penn, C. W. Avoidance of host defences by Treponema pallidum in situ and on extraction from infected rabbit testes. J. Gen. Microbiol. 126, 69–75 (1981).

    Google Scholar 

  5. 5

    Stamm, L. V., Hodinka, R. L., Wyrick, P. B. & Bassford, P. J. Changes in the cell surface properties of Treponema pallidum that occur during in vitro incubation of freshly extracted organisms. Infect. Immun. 55, 2255–2261 (1987).

    Google Scholar 

  6. 6

    Salazar, J. C., Rathi, A., Michael, N. L., Radolf, J. D. & Jagodzinski, L. L. Assessment of the kinetics of Treponema pallidum dissemination into blood and tissues in experimental syphilis by real-time quantitative PCR. Infect. Immun. 75, 2954–2958 (2007).

    Google Scholar 

  7. 7

    Thomas, D. D. et al. Treponema pallidum invades intercellular junctions of endothelial cell monolayers. Proc. Natl Acad. Sci. USA 85, 3608–3612 (1988).

    Google Scholar 

  8. 8

    LaFond, R. E. & Lukehart, S. A. Biological basis for syphilis. Clin. Microbiol. Rev. 19, 29–49 (2006).

    Google Scholar 

  9. 9

    Radolf, J. D., Tramont, E. C. & Salazar, J. C. in Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases 8 th edn (eds Bennett, J. E., Dolin, R. & Blaser, M. J. ) 2684–2709 (Saunders, 2014).

    Google Scholar 

  10. 10

    Cruz, A. R. et al. Immune evasion and recognition of the syphilis spirochete in blood and skin of secondary syphilis patients: two immunologically distinct compartments. PLoS Negl. Trop. Dis. 6, e1717 (2012).

    Google Scholar 

  11. 11

    World Health Organisation. WHO guidelines for the treatment of Treponema pallidum (syphilis). WHO (2016).

  12. 12

    Workowski, K. A. & Bolan, G. A. & Centers for Disease Control & Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen. Rep. 64, 1–137 (2015).

    Google Scholar 

  13. 13

    Janier, M. et al. 2014 European guideline on the management of syphilis. J. Eur. Acad. Dermatol. Venereol. 28, 1581–1593 (2014).

    Google Scholar 

  14. 14

    Peeling, R. W. & Hook, E. W. The pathogenesis of syphilis: the Great Mimicker, revisited. J. Pathol. 208, 224–232 (2005).

    Google Scholar 

  15. 15

    Rolfs, R. T. et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N. Engl. J. Med. 337, 307–314 (1997).

    Google Scholar 

  16. 16

    Golden, M. R., Marra, C. M. & Holmes, K. K. Update on syphilis. JAMA 290, 1510 (2003).

    Google Scholar 

  17. 17

    Lukehart, S. A. et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann. Intern. Med. 109, 855–862 (1988).

    Google Scholar 

  18. 18

    Shaffi, T., Radolf, J. D., Sanchez, P. J., Schulz, K. F. & Murphy, F. K. in Sexually Transmitted Diseases 4th edn (eds Holmes, K. K. et al. ) 1577 –1609 (McGraw-Hill Medical, 2008).

    Google Scholar 

  19. 19

    Sánchez, P. J. et al. Evaluation of molecular methodologies and rabbit infectivity testing for the diagnosis of congenital syphilis and neonatal central nervous system invasion by Treponema pallidum. J. Infect. Dis. 167, 148–157 (1993).

    Google Scholar 

  20. 20

    Fiurmara, N. J. Congenital syphilis in Massachusetts. N. Engl. J. Med. 245, 634–640 (1951).

    Google Scholar 

  21. 21

    Watson-Jones, D. et al. Syphilis in pregnancy in Tanzania. I. Impact maternal syphilis outcome pregnancy. J. Infect. Dis. 186, 940–947 (2002). A comprehensive and well-designed study that showed the outcomes of syphilis during pregnancy.

    Google Scholar 

  22. 22

    Magnuson, H. J., Eagle, H. & Fleischman, R. The minimal infectious inoculum of Spirochaeta pallida (Nichols strain) and a consideration of its rate of multiplication in vivo. Am. J. Syph. Gonorrhea Vener. Dis. 32, 1–18 (1948).

    Google Scholar 

  23. 23

    Newman, L. et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 10, e1001396 (2013).

    Google Scholar 

  24. 24

    Wijesooriya, N. S. et al. Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study. Lancet Glob. Health 4, e525–e533 (2016). This paper is one of three WHO studies that have provided the backbone of our data on the global burden of syphilis; it provided updated global estimates in pregnant women and of adverse pregnancy outcomes 5 years into the global programme for congenital syphilis elimination (that is, monitoring progress).

    Google Scholar 

  25. 25

    Lawn, J. E. et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 387, 587–603 (2016). The first paper that showed that syphilis has emerged as the leading cause of preventable stillbirths.

    Google Scholar 

  26. 26

    Hook, E. W. & Peeling, R. W. Syphilis control — a continuing challenge. N. Engl. J. Med. 351, 122–124 (2004).

    Google Scholar 

  27. 27

    Newman, L. et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE 10, e0143304 (2015).

    Google Scholar 

  28. 28

    Black, V. et al. Field evaluation of Standard Diagnostics’ Bioline HIV/Syphilis Duo test among female sex workers in Johannesburg, South Africa. Sex. Transm. Infect. 92, 495–498 (2016).

    Google Scholar 

  29. 29

    Elhadi, M. et al. Integrated bio-behavioural HIV surveillance surveys among female sex workers in Sudan, 2011–2012. Sex. Transm. Infect. 89, S17–S22 (2013).

    Google Scholar 

  30. 30

    Vandepitte, J. et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sex. Transm. Dis. 38, 316–323 (2011).

    Google Scholar 

  31. 31

    McLaughlin, M. M. et al. Sexually transmitted infections among heterosexual male clients of female sex workers in China: a systematic review and meta-analysis. PLoS ONE 8, e71394 (2013).

    Google Scholar 

  32. 32

    Su, S. et al. Sustained high prevalence of viral hepatitis and sexually transmissible infections among female sex workers in China: a systematic review and meta-analysis. BMC Infect. Dis. 16, 2 (2015).

    Google Scholar 

  33. 33

    Chen, X.-S. et al. Prevalence of syphilis infection in different tiers of female sex workers in China: implications for surveillance and interventions. BMC Infect. Dis. 12, 84 (2012).

    Google Scholar 

  34. 34

    Abara, W. E., Hess, K. L., Neblett Fanfair, R., Bernstein, K. T. & Paz-Bailey, G. Syphilis trends among men who have sex with men in the United States and western Europe: a systematic review of trend studies published between 2004 and 2015. PLoS ONE 11, e0159309 (2016). A good review that described the alarming increase of syphilis in MSM in the developed world.

    Google Scholar 

  35. 35

    de Voux, A. et al. State-specific rates of primary and secondary syphilis among men who have sex with men - United States, 2015. MMWR. Morb. Mortal. Wkly Rep. 66, 349–354 (2017).

    Google Scholar 

  36. 36

    Burchell, A. N. et al. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect. Dis. 15, 356 (2015).

    Google Scholar 

  37. 37

    Centers for Disease Control and Prevention. Syphilis treatment and care. Centers for Disease Control and Prevention (2015).

  38. 38

    Brodsky, J. L. et al. Syphilis outbreak at a California men's prison, 2007-2008: propagation by lapses in clinical management, case management, and public health surveillance. J. Correct. Health Care 19, 54–64 (2012).

    Google Scholar 

  39. 39

    Van Wagoner, N. J., Harbison, H. S., Drewry, J., Turnipseed, E. & Hook, E. W. Characteristics of women reporting multiple recent sex partners presenting to a sexually transmitted disease clinic for care. Sex. Transm. Dis. 38, 210–215 (2011).

    Google Scholar 

  40. 40

    Bibbins-Domingo, K. et al. Screening for syphilis infection in nonpregnant adults and adolescents. JAMA 315, 2321 (2016).

    Google Scholar 

  41. 41

    European Centre for Disease Prevention and Control. Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA. European Centre for Disease Prevention and Control (2017).

  42. 42

    Rekart, M. L. et al. A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum? Sex. Transm. Infect. 93, 374–378 (2017). This paper presented an interesting hypothesis to explain the twin epidemics of HIV and syphilis in MSM.

    Google Scholar 

  43. 43

    Schmid, G. P., Stoner, B. P., Hawkes, S. & Broutet, N. The need and plan for global elimination of congenital syphilis. Sex. Transm. Dis. 34, S5–S10 (2007).

    Google Scholar 

  44. 44

    World Health Organisation. The global elimination of congenital syphilis: rationale and strategy for action. WHO (2007).

  45. 45

    Gomez, G. B. et al. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull. World Health Organ. 91, 217–226 (2013).

    Google Scholar 

  46. 46

    Blencowe, H., Cousens, S., Kamb, M., Berman, S. & Lawn, J. E. Lives Saved Tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality. BMC Public Health 11, S9 (2011).

    Google Scholar 

  47. 47

    WHO. Investment case for eliminating mother-to-child transmission of syphilis. WHO (2012).

  48. 48

    Kahn, J. G. et al. The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model. PLoS ONE 9, e87510 (2014).

    Google Scholar 

  49. 49

    Kuznik, A., Lamorde, M., Nyabigambo, A. & Manabe, Y. C. Antenatal syphilis screening using point-of-care testing in sub-Saharan African countries: a cost-effectiveness analysis. PLoS Med. 10, e1001545 (2013).

    Google Scholar 

  50. 50

    Kuznik, A., Muhumuza, C., Komakech, H., Marques, E. M. R. & Lamorde, M. Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis. PLoS ONE 10, e0127379 (2015).

    Google Scholar 

  51. 51

    Owusu-Edusei, K. et al. Cost-effectiveness of integrated routine offering of prenatal HIV and syphilis screening in China. Sex. Transm. Dis. 41, 103–110 (2014).

    Google Scholar 

  52. 52

    Pan American Health Organization. Regional initiative for the elimination of mother-to-child transmission of HIV and congenital syphilis in Latin America and the Caribbean. Concept document for the Caribbean. Pan American Health Organization (2009).

  53. 53

    Chen, X., Yin, Y., Wang, Q. & Wang, B. Historical perspective of syphilis in the past 60 years in China: eliminated, forgotten, on the return. Chin. Med. J. (Engl.). 126, 2774–2779 (2013). Many lessons can be learnt from this account of the history of syphilis in China, which was once eliminated but has now come back with a vengeance.

    Google Scholar 

  54. 54

    Taylor, M. et al. Elimination of mother-to-child transmission of HIV and Syphilis (EMTCT): process, progress, and program integration. PLoS Med. 14, e1002329 (2017). This paper described a success story of syphilis control and elimination, and highlighted how continuing global efforts can achieve an AIDS-free and syphilis-free generation.

    Google Scholar 

  55. 55

    Norris, S. J., Cox, D. L. & Weinstock, G. M. Biology of Treponema pallidum: correlation of functional activities with genome sequence data. J. Mol. Microbiol. Biotechnol. 3, 37–62 (2001).

    Google Scholar 

  56. 56

    Penn, C. W., Cockayne, A. & Bailey, M. J. The outer membrane of Treponema pallidum: biological significance and biochemical properties. J. Gen. Microbiol. 131, 2349–2357 (1985).

    Google Scholar 

  57. 57

    Radolf, J. D. Treponema pallidum and the quest for outer membrane proteins. Mol. Microbiol. 16, 1067–1073 (1995).

    Google Scholar 

  58. 58

    Silver, A. C. et al. MyD88 deficiency markedly worsens tissue inflammation and bacterial clearance in mice infected with Treponema pallidum, the agent of syphilis. PLoS ONE 8, e71388 (2013).

    Google Scholar 

  59. 59

    Turner, T. B., Hardy, P. H. & Newman, B. Infectivity tests in syphilis. Sex. Transm. Infect. 45, 183–195 (1969).

    Google Scholar 

  60. 60

    Lukehart, S. A. & Marra, C. M. Current Protocols in Microbiology (John Wiley and Sons, Inc., 2007).

    Google Scholar 

  61. 61

    Sell, S. & Norris, S. J. The biology, pathology, and immunology of syphilis. Int. Rev. Exp. Pathol. 24, 203–276 (1983).

    Google Scholar 

  62. 62

    Lukehart, S. A. Scientific monogamy: thirty years dancing with the same bug. Sex. Transm. Dis. 35, 2–7 (2008).

    Google Scholar 

  63. 63

    Radolf, J. D. et al. Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen. Nat. Rev. Microbiol. 14, 744–759 (2016). The review provided a very informative summary of the interaction of T. pallidum and its human hosts.

    Google Scholar 

  64. 64

    Paster, B. J. & Dewhirst, F. in Pathogenic Treponema: Molecular and Cellular Biology (eds Radolf, J. D. & Lukehart, S. A. ) 9–18 (Horizon Scientific Press, 2006).

    Google Scholar 

  65. 65

    Fraser, C. M. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 281, 375–388 (1998).

    Google Scholar 

  66. 66

    Radolf, J. D. et al. Characterization of outer membranes isolated from Treponema pallidum, the syphilis spirochete. Infect. Immun. 63, 4244–4252 (1995).

    Google Scholar 

  67. 67

    Cox, D. L., Akins, D. R., Porcella, S. F., Norgard, M. V. & Radolf, J. D. Treponema pallidum in gel microdroplets: a novel strategy for investigation of treponemal molecular architecture. Mol. Microbiol. 15, 1151–1164 (1995).

    Google Scholar 

  68. 68

    Radolf, J. D., Hazlett, K. R. O. & Lukehart, S. A. in Pathogenic Treponemes: Cellular and Molecular Biology (eds Radolf, J. D. & Lukehart, S. A. ) 197–236 (Horizon Scientific Press, 2006).

    Google Scholar 

  69. 69

    Salazar, J. C., Hazlett, K. R. O. & Radolf, J. D. The immune response to infection with Treponema pallidum, the stealth pathogen. Microbes Infect. 4, 1133–1140 (2002).

    Google Scholar 

  70. 70

    Chamberlain, N. R., Brandt, M. E., Erwin, A. L., Radolf, J. D. & Norgard, M. V. Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect. Immun. 57, 2872–2877 (1989).

    Google Scholar 

  71. 71

    Purcell, B. K., Swancutt, M. A. & Radolf, J. D. Lipid modification of the 15 kiloDalton major membrane immunogen of Treponema pallidum. Mol. Microbiol. 4, 1371–1379 (1990).

    Google Scholar 

  72. 72

    Akins, D. R., Purcell, B. K., Mitra, M. M., Norgard, M. V. & Radolf, J. D. Lipid modification of the 17-kilodalton membrane immunogen of Treponema pallidum determines macrophage activation as well as amphiphilicity. Infect. Immun. 61, 1202–1210 (1993).

    Google Scholar 

  73. 73

    Radolf, J. D., Chamberlain, N. R., Clausell, A. & Norgard, M. V. Identification and localization of integral membrane proteins of virulent Treponema pallidum subsp. pallidum by phase partitioning with the nonionic detergent triton X-114. Infect. Immun. 56, 490–498 (1988).

    Google Scholar 

  74. 74

    Cox, D. L., Chang, P., McDowall, A. W. & Radolf, J. D. The outer membrane, not a coat of host proteins, limits antigenicity of virulent Treponema pallidum. Infect. Immun. 60, 1076–1083 (1992).

    Google Scholar 

  75. 75

    Deka, R. K. et al. Crystal structure of the Tp34 (TP0971) lipoprotein of Treponema pallidum: implications of its metal-bound state and affinity for human lactoferrin. J. Biol. Chem. 282, 5944–5958 (2006).

    Google Scholar 

  76. 76

    Cameron, C. E., Brouwer, N. L., Tisch, L. M. & Kuroiwa, J. M. Y. Defining the interaction of the Treponema pallidum adhesin Tp0751 with laminin. Infect. Immun. 73, 7485–7494 (2005).

    Google Scholar 

  77. 77

    Houston, S., Hof, R., Honeyman, L., Hassler, J. & Cameron, C. E. Activation and proteolytic activity of the Treponema pallidum metalloprotease, pallilysin. PLoS Pathog. 8, e1002822 (2012).

    Google Scholar 

  78. 78

    Houston, S. et al. The multifunctional role of the pallilysin-associated Treponema pallidum protein, Tp0750, in promoting fibrinolysis and extracellular matrix component degradation. Mol. Microbiol. 91, 618–634 (2014).

    Google Scholar 

  79. 79

    Parker, M. L. et al. The structure of Treponema pallidum Tp0751 (pallilysin) reveals a non-canonical lipocalin fold that mediates adhesion to extracellular matrix components and interactions with host cells. PLOS Pathog. 12, e1005919 (2016).

    Google Scholar 

  80. 80

    Cameron, C. E. et al. Heterologous expression of the Treponema pallidum laminin-binding adhesin Tp0751 in the culturable spirochete Treponema phagedenis. J. Bacteriol. 190, 2565–2571 (2008).

    Google Scholar 

  81. 81

    Lithgow, K. V. et al. A defined syphilis vaccine candidate inhibits dissemination of Treponema pallidum subspecies pallidum. Nat. Commun. 8, 14273 (2017).

    Google Scholar 

  82. 82

    Chan, K. et al. Treponema pallidum lipoprotein TP0435 expressed in Borrelia burgdorferi produces multiple surface/periplasmic isoforms and mediates adherence. Sci. Rep. 6, 25593 (2016).

    Google Scholar 

  83. 83

    Luthra, A. et al. The transition from closed to open conformation of Treponema pallidum outer membrane-associated lipoprotein TP0453 involves membrane sensing and integration by two amphipathic helices. J. Biol. Chem. 286, 41656–41668 (2011).

    Google Scholar 

  84. 84

    Desrosiers, D. C. et al. TP0326, a Treponema pallidum β-barrel assembly machinery A (BamA) orthologue and rare outer membrane protein. Mol. Microbiol. 80, 1496–1515 (2011).

    Google Scholar 

  85. 85

    Luthra, A. et al. A homology model reveals novel structural features and an immunodominant surface loop/opsonic target in the Treponema pallidum BamA ortholog TP_0326. J. Bacteriol. 197, 1906–1920 (2015).

    Google Scholar 

  86. 86

    Rollauer, S. E., Sooreshjani, M. A., Noinaj, N. & Buchanan, S. K. Outer membrane protein biogenesis in Gram-negative bacteria. Phil. Trans. R. Soc. B Biol. Sci. 370, 20150023 (2015).

    Google Scholar 

  87. 87

    Centurion-Lara, A. et al. Treponema pallidum major sheath protein homologue Tpr K is a target of opsonic antibody and the protective immune response. J. Exp. Med. 189, 647–656 (1999).

    Google Scholar 

  88. 88

    Hazlett, K. R. O. et al. The Tprk protein of Treponema pallidum is periplasmic and is not a target of opsonic antibody or protective immunity. J. Exp. Med. 193, 1015–1026 (2001).

    Google Scholar 

  89. 89

    Centurion-Lara, A. et al. Gene conversion: a mechanism for generation of heterogeneity in the tprK gene of Treponema pallidum during infection. Mol. Microbiol. 52, 1579–1596 (2004).

    Google Scholar 

  90. 90

    LaFond, R. E., Centurion-Lara, A., Godornes, C., Van Voorhis, W. C. & Lukehart, S. A. TprK sequence diversity accumulates during infection of rabbits with Treponema pallidum subsp. pallidum Nichols strain. Infect. Immun. 74, 1896–1906 (2006).

    Google Scholar 

  91. 91

    Giacani, L. et al. Antigenic variation in Treponema pallidum: TprK sequence diversity accumulates in response to immune pressure during experimental syphilis. J. Immunol. 184, 3822–3829 (2010).

    Google Scholar 

  92. 92

    Pinto, M. et al. Genome-scale analysis of the non-cultivable Treponema pallidum reveals extensive within-patient genetic variation. Nat. Microbiol. 2, 16190 (2016).

    Google Scholar 

  93. 93

    Anand, A. et al. TprC/D (Tp0117/131), a trimeric, pore-forming rare outer membrane protein of Treponema pallidum, has a bipartite domain structure. J. Bacteriol. 194, 2321–2333 (2012).

    Google Scholar 

  94. 94

    Anand, A. et al. Bipartite topology of Treponema pallidum repeat proteins C/D and I: outer membrane insertion, trimerization, and porin function require a C-terminal β-barrel domain. J. Biol. Chem. 290, 12313–12331 (2015).

    Google Scholar 

  95. 95

    Giacani, L. et al. TP0262 is a modulator of promoter activity of tpr subfamily II genes of Treponema pallidum ssp. pallidum. Mol. Microbiol. 72, 1087–1099 (2009).

    Google Scholar 

  96. 96

    Radolf, J. D. & Desrosiers, D. C. Treponema pallidum, the stealth pathogen, changes, but how? Mol. Microbiol. 72, 1081–1086 (2009).

    Google Scholar 

  97. 97

    Brinkman, M. B. et al. A novel Treponema pallidum antigen, TP0136, is an outer membrane protein that binds human fibronectin. Infect. Immun. 76, 1848–1857 (2008).

    Google Scholar 

  98. 98

    Cameron, C. E., Brown, E. L., Kuroiwa, J. M. Y., Schnapp, L. M. & Brouwer, N. L. Treponema pallidum fibronectin-binding proteins. J. Bacteriol. 186, 7019–7022 (2004).

    Google Scholar 

  99. 99

    Ke, W., Molini, B. J., Lukehart, S. A. & Giacani, L. Treponema pallidum subsp. pallidum TP0136 protein is heterogeneous among isolates and binds cellular and plasma fibronectin via its NH2-terminal end. PLoS Negl. Trop. Dis. 9, e0003662 (2015).

    Google Scholar 

  100. 100

    Harman, M., Vig, D. K., Radolf, J. D. & Wolgemuth, C. W. Viscous dynamics of Lyme disease and syphilis spirochetes reveal flagellar torque and drag. Biophys. J. 105, 2273–2280 (2013).

    Google Scholar 

  101. 101

    Riley, B. S., Oppenheimer-Marks, N., Hansen, E. J., Radolf, J. D. & Norgard, M. V. Virulent Treponema pallidum activates human vascular endothelial cells. J. Infect. Dis. 165, 484–493 (1992).

    Google Scholar 

  102. 102

    Quatresooz, P. & Piérard, G. E. Skin homing of Treponema pallidum in early syphilis: an immunohistochemical study. Appl. Immunohistochem. Mol. Morphol. 17, 47–50 (2009).

    Google Scholar 

  103. 103

    Bouis, D. A., Popova, T. G., Takashima, A. & Norgard, M. V. Dendritic cells phagocytose and are activated by Treponema pallidum. Infect. Immun. 69, 518–528 (2001).

    Google Scholar 

  104. 104

    Moore, M. W. et al. Phagocytosis of Borrelia burgdorferi and Treponema pallidum potentiates innate immune activation and induces gamma interferon production. Infect. Immun. 75, 2046–2062 (2007).

    Google Scholar 

  105. 105

    Salazar, J. C. et al. Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. J. Infect. Dis. 195, 879–887 (2007).

    Google Scholar 

  106. 106

    Stary, G. et al. Host defense mechanisms in secondary syphilitic lesions. Am. J. Pathol. 177, 2421–2432 (2010).

    Google Scholar 

  107. 107

    Van Voorhis, W. C. et al. Primary and secondary syphilis lesions contain mRNA for Th1 cytokines. J. Infect. Dis. 173, 491–495 (1996).

    Google Scholar 

  108. 108

    Van Voorhis, W. C., Barrett, L. K., Nasio, J. M., Plummer, F. A. & Lukehart, S. A. Lesions of primary and secondary syphilis contain activated cytolytic T cells. Infect. Immun. 64, 1048–1050 (1996).

    Google Scholar 

  109. 109

    McBroom, R. L. et al. Secondary syphilis in persons infected with and not infected with HIV-1: a comparative immunohistologic study. Am. J. Dermatopathol. 21, 432 (1999).

    Google Scholar 

  110. 110

    Radolf, J. D. & Lukehart, S. A. in Pathogenic Treponemes: Cellular and Molecular Biology (eds Radolf, J. D. & Lukehart, S. A. ) 285–322 (Horizon Scientific Press, 2006).

    Google Scholar 

  111. 111

    Lukehart, S. A. L., Shaffer, J. M. & Baker-Zander, S. A. Subpopulation of Treponema pallidum is resistant to phagocytosis: possible mechanism of persistence. J. Infect. Dis. 166, 1449–1453 (1992).

    Google Scholar 

  112. 112

    Cox, D. L. et al. Surface immunolabeling and consensus computational framework to identify candidate rare outer membrane proteins of Treponema pallidum. Infect. Immun. 78, 5178–5194 (2010).

    Google Scholar 

  113. 113

    Nelson, R. A. Jr. & Mayer, M. M. Immobilization of Treponema pallidum in vitro by antibody produced in syphilitic infection. J. Exp. Med. 89, 369–393 (1949).

    Google Scholar 

  114. 114

    Bishop, N. H. & Miller, J. N. Humoral immunity in experimental syphilis. II. The relationship of neutralizing factors in immune serum to acquired resistance. J. Immunol. 117, 197–207 (1976).

    Google Scholar 

  115. 115

    Giacani, L., Lukehart, S. & Centurion-Lara, A. Length of guanosine homopolymeric repeats modulates promoter activity of subfamily II tpr genes of Treponema pallidum ssp. pallidum. FEMS Immunol. Med. Microbiol. 51, 289–301 (2007).

    Google Scholar 

  116. 116

    Giacani, L. et al. Transcription of TP0126, Treponema pallidum putative OmpW Homolog, is regulated by the length of a homopolymeric guanosine repeat. Infect. Immun. 83, 2275–2289 (2015).

    Google Scholar 

  117. 117

    Deitsch, K. W., Lukehart, S. A. & Stringer, J. R. Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. Nat. Rev. Microbiol. 7, 493–503 (2009).

    Google Scholar 

  118. 118

    Harter, C. & Benirschke, K. Fetal syphilis in the first trimester. Am. J. Obstet. Gynecol. 124, 705–711 (1976).

    Google Scholar 

  119. 119

    Qin, J. et al. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. PLoS ONE 9, e102203 (2014). Together with Ref. 45, these two large systematic reviews estimated the extent of adverse pregnancy outcomes caused by untreated maternal syphilis and provided our best evidence on adverse pregnancy outcomes associated with syphilis.

    Google Scholar 

  120. 120

    Muller, I. et al. Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the German Infection Serology Proficiency Testing Program. J. Clin. Microbiol. 44, 1335–1341 (2006).

    Google Scholar 

  121. 121

    Parekh, B. S. et al. Dried tube specimens: a simple and cost-effective method for preparation of HIV proficiency testing panels and quality control materials for use in resource-limited settings. J. Virol. Methods 163, 295–300 (2010).

    Google Scholar 

  122. 122

    Beber, A. M. B., Sabidó, M., Vieira, J. M. R., Bazzo, M. L. & Benzaken, A. S. External quality assessment in the voluntary counseling and testing centers in the Brazilian Amazon using dried tube specimens: results of an effectiveness evaluation. Rev. Soc. Bras. Med. Trop. 48, 87–97 (2015).

    Google Scholar 

  123. 123

    Benzaken, A. S. et al. External quality assurance with dried tube specimens (DTS) for point-of-care syphilis and HIV tests: experience in an indigenous populations screening programme in the Brazilian Amazon. Sex. Transm. Infect. 90, 14–18 (2013).

    Google Scholar 

  124. 124

    Smit, P. W. et al. The development and validation of dried blood spots for external quality assurance of syphilis serology. BMC Infect. Dis. 13, 102 (2013).

    Google Scholar 

  125. 125

    Sparling, P. F. in Sexually Transmitted Diseases 3rd edn (eds Holmes, K. K., Sparling, P. F. & Mardh, P. A. ) 473–478 (McGraw-Hill Medical, 1999).

    Google Scholar 

  126. 126

    Centre for Disease Control and Prevention & Pan American Health Organization. Syphilis testing practices in the Americas region: results of the 2014 survey. Pan American Health Organization (2016).

  127. 127

    Chi, K.-H. et al. Molecular differentiation of Treponema pallidum subspecies in skin ulceration clinically suspected as yaws in Vanuatu using real-time multiplex PCR and serological methods. Am. J. Trop. Med. Hyg. 92, 134–138 (2014).

    Google Scholar 

  128. 128

    Liu, H., Rodes, B., Chen, C.-Y. & Steiner, B. New tests for syphilis: rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase I Gene. J. Clin. Microbiol. 39, 1941–1946 (2001).

    Google Scholar 

  129. 129

    Gayet-Ageron, A., Lautenschlager, S., Ninet, B., Perneger, T. V. & Combescure, C. Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis. Sex. Transm. Infect. 89, 251–256 (2013).

    Google Scholar 

  130. 130

    Castro, R. et al. Detection of Treponema pallidum sp. pallidum DNA in cerebrospinal fluid (CSF) by two PCR techniques. J. Clin. Lab. Anal. 30, 628–632 (2016).

    Google Scholar 

  131. 131

    Fraga, D. et al. Detection of Treponema pallidum by semi-nested PCR in the cerebrospinal fluid of asymptomatic HIV-infected patients with latent syphilis. Clin. Lab. 60, 2051–2054 (2014).

    Google Scholar 

  132. 132

    Creegan, L. et al. An evaluation of the relative sensitivities of the venereal disease research laboratory test and the Treponema pallidum particle agglutination test among patients diagnosed with primary syphilis. Sex. Transm. Dis. 34, 1016–1018 (2007).

    Google Scholar 

  133. 133

    Wende, R. D., Mudd, R. L., Know, J. M. & Holder, W. R. The VDRL slide test in 322 cases of darkfield positive primary syphilis. South. Med. J. 64, 633–634 (1971).

    Google Scholar 

  134. 134

    Peeling, R. W., Holmes, K. K., Mabey, D. & Ronald, A. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex. Transm. Infect. 82 (Suppl. 5), 1–6 (2006).

    Google Scholar 

  135. 135

    Pastuszczak, M. et al. Robust pro-inflammatory immune response is associated with serological cure in patients with syphilis: an observational study. Sex. Transm. Infect. 93, 11–14 (2016).

    Google Scholar 

  136. 136

    Larsen, S. A. & Johnson, R. E. A Manual of Tests for Syphilis: Diagnostic Tests 9th edn (1998).

  137. 137

    Sparling, P. F. Diagnosis and treatment of syphilis. N. Engl. J. Med. 284, 642–653 (1971).

    Google Scholar 

  138. 138

    Fiumara, N. J. Posttreatment serological response of biologic false-positive reactors. JAMA 247, 817–818 (1982).

    Google Scholar 

  139. 139

    Donkers, A., Levy, H. R. & Letens-van Vliet, A. Syphilis detection using the Siemens ADVIA Centaur Syphilis treponemal assay. Clin. Chim. Acta 433, 84–87 (2014).

    Google Scholar 

  140. 140

    Gomez, E., Jespersen, D. J., Harring, J. A. & Binnicker, M. J. Evaluation of the Bio-Rad BioPlex 2200 syphilis multiplex flow immunoassay for the detection of IgM- and IgG-class antitreponemal antibodies. Clin. Vaccine Immunol. 17, 966–968 (2010).

    Google Scholar 

  141. 141

    Sambri, V. et al. Western immunoblotting with five Treponema pallidum recombinant antigens for serologic diagnosis of syphilis. Clin. Vaccine Immunol. 8, 534–539 (2001).

    Google Scholar 

  142. 142

    Wong, E. H. et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. Sex. Transm. Dis. 38, 528–532 (2011).

    Google Scholar 

  143. 143

    Centers for Disease Control and Prevention (CDC). Discordant results from reverse sequence syphilis screening — five laboratories, United States, 2006–2010. MMWR Morb. Mortal. Wkly Rep. 60, 133–137 (2011).

    Google Scholar 

  144. 144

    Centers for Disease Control and Prevention (CDC). Syphilis testing algorithms using treponemal tests for initial screening — four laboratories, New York City, 2005–2006. MMWR Morb. Mortal. Wkly Rep. 57, 872–875 (2008).

    Google Scholar 

  145. 145

    Peeling, R. W. & Ye, H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bull. World Health Organ. 82, 439–446 (2004).

    Google Scholar 

  146. 146

    Benzaken, A. S. et al. Field performance of a rapid point-of-care diagnostic test for antenatal syphilis screening in the Amazon region. Int. J. STD AIDS 22, 15–18 (2011).

    Google Scholar 

  147. 147

    Mabey, D. et al. Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex. Transm. Infect. 82 (Suppl. 5), 13–16 (2006).

    Google Scholar 

  148. 148

    Mabey, D. C. et al. Point-of-care tests to strengthen health systems and save newborn lives: the case of syphilis. PLoS Med. 9, e1001233 (2012).

    Google Scholar 

  149. 149

    Siedner, M., Zapitz, V., Ishida, M., De La Roca, R. & Klausner, J. D. Performance of rapid syphilis tests in venous and fingerstick whole blood specimens. Sex. Transm. Dis. 31, 557–560 (2004).

    Google Scholar 

  150. 150

    Tinajeros, F. et al. Diagnostic accuracy of a point-of-care syphilis test when used among pregnant women in Bolivia. Sex. Transm. Infect. 82 (Suppl. 5), 17–21 (2006).

    Google Scholar 

  151. 151

    West, B. Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of syphilis in field conditions in rural Africa. Sex. Transm. Infect. 78, 282–285 (2002).

    Google Scholar 

  152. 152

    Gianino, M. M. et al. Performance and costs of a rapid syphilis test in an urban population at high risk for sexually transmitted infections. J. Prev. Med. Hyg. 48, 118–122 (2007).

    Google Scholar 

  153. 153

    Hernández-Trejo, M., Hernández-Prado, B., Uribe-Salas, F., Juárez-Figueroa, L. & Conde-González, C. J. Maternal and congenital syphilis in two Mexican hospitals: evaluation of a rapid diagnostic test [Spanish]. Rev. Invest. Clin. 58, 119–125 (2006).

    Google Scholar 

  154. 154

    Lien, T. X. et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City. Am. J. Trop. Med. Hyg. 62, 301–309 (2000).

    Google Scholar 

  155. 155

    Galvao, T. F. et al. Safety of benzathine penicillin for preventing congenital syphilis: a systematic review. PLoS ONE 8, e56463 (2013).

    Google Scholar 

  156. 156

    Castro, A. R. et al. Novel point-of-care test for simultaneous detection of nontreponemal and treponemal antibodies in patients with syphilis. J. Clin. Microbiol. 48, 4615–4619 (2010).

    Google Scholar 

  157. 157

    Yin, Y.-P. et al. A dual point-of-care test shows good performance in simultaneously detecting nontreponemal and treponemal antibodies in patients with syphilis: a multisite evaluation study in China. Clin. Infect. Dis. 56, 659–665 (2012).

    Google Scholar 

  158. 158

    Causer, L. M. et al. An evaluation of a novel dual treponemal/nontreponemal point-of-care test for syphilis as a tool to distinguish active from past treated infection. Clin. Infect. Dis. 61, 184–191 (2015).

    Google Scholar 

  159. 159

    Gliddon, H. D. et al. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex. Transm. Infect. (2017).

  160. 160

    Ghanem, K. G. & Workowski, K. A. Management of adult syphilis. Clin. Infect. Dis. 53 (Suppl. 3), 110–128 (2011).

    Google Scholar 

  161. 161

    Kingston, M. et al. UK national guidelines on the management of syphilis 2015. Int. J. STD AIDS 27, 421–446 (2016).

    Google Scholar 

  162. 162

    Marra, C. M. et al. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex. Transm. Dis. 39, 453–457 (2012).

    Google Scholar 

  163. 163

    Marra, C. M., Tantalo, L. C., Maxwell, C. L., Dougherty, K. & Wood, B. Alternative cerebrospinal fluid tests to diagnose neurosyphilis in HIV-infected individuals. Neurology 63, 85–88 (2004).

    Google Scholar 

  164. 164

    Marra, C. M., Maxwell, C. L., Dunaway, S. B., Sahi, S. K. & Tantalo, L. C. Cerebrospinal Fluid Treponema pallidum particle agglutination assay for neurosyphilis diagnosis. J. Clin. Microbiol. 55, 1865–1870 (2017).

    Google Scholar 

  165. 165

    Marra, C. M. et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J. Infect. Dis. 189, 369–376 (2004).

    Google Scholar 

  166. 166

    Meyers, D. et al. USPSTF recommendations for STI screening. Am. Fam. Physician 77, 819–824 (2008).

    Google Scholar 

  167. 167

    Owusu-Ofori, A., Parry, C. & Bates, I. Transfusion-transmitted syphilis in teaching hospital. Emerg. Infect. Dis. 17, 2080–2082 (2011).

    Google Scholar 

  168. 168

    Food and Drug Administration. Requirements for blood and blood components intended for transfusion or for further manufacturing use; Federal Register, Rules and Regulations. Government Publishing Office (2015).

  169. 169

    Tapko, J. B., Toure, B. & Sambo, L. G. Status of blood safety in the WHO African region: report of the 2010 survey. World Health Organization (2014).

  170. 170

    Hossain, M., Broutet, N. & Hawkes, S. The elimination of congenital syphilis: a comparison of the proposed World Health Organization action plan for the elimination of congenital syphilis with existing national maternal and congenital syphilis policies. Sex. Transm. Dis. 34, S22–S30 (2007).

    Google Scholar 

  171. 171

    Hawkes, S., Matin, N., Broutet, N. & Low, N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect. Dis. 11, 684–691 (2011). This systematic review of 10 studies showed that interventions to improve the coverage and effect of screening programmes for antenatal syphilis could reduce the syphilis-attributable incidence of stillbirth and perinatal death by 50%.

    Google Scholar 

  172. 172

    Swartzendruber, A., Steiner, R. J., Adler, M. R., Kamb, M. L. & Newman, L. M. Introduction of rapid syphilis testing in antenatal care: a systematic review of the impact on HIV and syphilis testing uptake and coverage. Int. J. Gynecol. Obstet. 130, S15–S21 (2015).

    Google Scholar 

  173. 173

    Valderrama, J., Zacarías, F. & Mazin, R. Sífilis materna y sífilis congénita en América Latina: un problema grave de solución sencilla [Spanish]. Rev. Panam. Salud Pública 16, 211–217 (2004).

    Google Scholar 

  174. 174

    Pan American Health Organization. Update 2014: elimination of mother-to-child transmission of HIV and syphilis in the Americas. Pan American Health Organization (2014).

  175. 175

    Cantor, A. G., Pappas, M., Daeges, M. & Nelson, H. D. Screening for syphilis. JAMA 315, 2328 (2016).

    Google Scholar 

  176. 176

    Tuite, A. & Fisman, D. Go big or go home: impact of screening coverage on syphilis infection dynamics. Sex. Transm. Infect. 92, 49–54 (2015).

    Google Scholar 

  177. 177

    Reed, J. L. et al. Adolescent patient preferences surrounding partner notification and treatment for sexually transmitted infections. Acad. Emerg. Med. 22, 61–66 (2014).

    Google Scholar 

  178. 178

    Tucker, J. D. et al. Organizational characteristics of HIV/syphilis testing services for men who have sex with men in South China: a social entrepreneurship analysis and implications for creating sustainable service models. BMC Infect. Dis. (2014).

  179. 179

    Tucker, J. D., Fenton, K. A., Peckham, R. & Peeling, R. W. Social Entrepreneurship for Sexual Health (SESH): a new approach for enabling delivery of sexual health services among most-at-risk populations. PLoS Med. 9, e1001266 (2012).

    Google Scholar 

  180. 180

    Dubourg, G. & Raoult, D. The challenges of preexposure prophylaxis for bacterial sexually transmitted infections. Clin. Microbiol. Infect. 22, 753–756 (2016).

    Google Scholar 

  181. 181

    Molina, J.-M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237–2246 (2015).

    Google Scholar 

  182. 182

    NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions et al. Infectious disease testing for blood transfusions. JAMA 274, 1374–1379 (1995).

    Google Scholar 

  183. 183

    Gardella, C., Marfin, A. A., Kahn, R. H., Swint, E. & Markowitz, L. E. Persons with early syphilis identified through blood or plasma donation screening in the United States. J. Infect. Dis. 185, 545–549 (2002).

    Google Scholar 

  184. 184

    Marfin, A. A. et al. Amplification of the DNA polymerase I gene of Treponema pallidum from whole blood of persons with syphilis. Diagn. Microbiol. Infect. Dis. 40, 163–166 (2001).

    Google Scholar 

  185. 185

    Chambers, R. W., Foley, H. T. & Schmidt, P. J. Transmission of syphilis by fresh blood components. Transfusion 9, 32–34 (1969).

    Google Scholar 

  186. 186

    Seña, A. C. et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect. Dis. 15, 479 (2015).

    Google Scholar 

  187. 187

    Seña, A. C. et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin. Infect. Dis. 53, 1092–1099 (2011).

    Google Scholar 

  188. 188

    Riedner, G. et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N. Engl. J. Med. 353, 1236–1244 (2005).

    Google Scholar 

  189. 189

    Hook III, E. W. et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J. Infect. Dis. 201, 1729–1735 (2010).

    Google Scholar 

  190. 190

    Lukehart, S. A. et al. Macrolide resistance inTreponema pallidum in the United States and Ireland. N. Engl. J. Med. 351, 154–158 (2004).

    Google Scholar 

  191. 191

    Zhou, P. et al. Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai. Sex. Transm. Dis. 37, 726–729 (2010).

    Google Scholar 

  192. 192

    Read, P. et al. Azithromycin-resistant syphilis-causing strains in Sydney, Australia: prevalence and risk factors. J. Clin. Microbiol. 52, 2776–2781 (2014).

    Google Scholar 

  193. 193

    Stamm, L. V. Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob. Agents Chemother. 54, 583–589 (2010).

    Google Scholar 

  194. 194

    Grillová, L. et al. Molecular typing of Treponema pallidum in the Czech Republic during 2011 to 2013: increased prevalence of identified genotypes and of isolates with macrolide resistance. J. Clin. Microbiol. 52, 3693–3700 (2014).

    Google Scholar 

  195. 195

    Ghanem, K. G. et al. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin. Infect. Dis. 47, 258–265 (2008).

    Google Scholar 

  196. 196

    Ghanem, K. G. et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 22, 1145–1151 (2008).

    Google Scholar 

  197. 197

    Tuddenham, S. & Ghanem, K. G. Emerging trends and persistent challenges in the management of adult syphilis. BMC Infect. Dis. 15, 351 (2015).

    Google Scholar 

  198. 198

    Zetola, N. M. & Klausner, J. D. Syphilis and HIV infection: an update. Clin. Infect. Dis. 44, 1222–1228 (2007).

    Google Scholar 

  199. 199

    Yang, C.-J. et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS ONE 9, e109667 (2014).

    Google Scholar 

  200. 200

    Ganesan, A. et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of hiv-infected persons with early syphilis. Clin. Infect. Dis. 60, 653–660 (2014).

    Google Scholar 

  201. 201

    Watson-Jones, D. et al. Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J. Infect. Dis. 186, 948–957 (2002).

    Google Scholar 

  202. 202

    Terris-Prestholt, F. Is antenatal syphilis screening still cost effective in sub-Saharan Africa. Sex. Transm. Infect. 79, 375–381 (2003).

    Google Scholar 

  203. 203

    Singh, A. E. & Romanowski, B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin. Microbiol. Rev. 12, 187–209 (1999). An excellent review that covered all aspects of syphilis.

    Google Scholar 

  204. 204

    Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines: Syphilis. Centers for Disease Control and Prevention (2015).

  205. 205

    Harman, N. B. in Venereal Disease 33–44 (Methuen & Company, Limited 1917).

    Google Scholar 

  206. 206

    Frith, J. Syphilis — its early history and treatment until penicillin and the debate on its origins. J. Mil. Veterans Health 20, 49–28 (2012).

    Google Scholar 

  207. 207

    Sartin, J. S. & Perry, H. O. From mercury to malaria to penicillin: the history of the treatment of syphilis at the Mayo Clinic — 1916–1955. J. Am. Acad. Dermatol. 32, 255–261 (1995).

    Google Scholar 

  208. 208

    Lopes, C., Powell, M. L. & Santos, A. L. Syphilis and cirrhosis: a lethal combination in a XIX century individual identified from the Medical Schools Collection at the University of Coimbra (Portugal). Mem. Inst. Oswaldo Cruz 105, 1050–1053 (2010).

    Google Scholar 

  209. 209

    Bjarne, B. The “rade” disease--a Norwegian tragedy [Norwegian]. Tidsskr. Nor. Laegeforen. 24, 3557–3558 (2003).

    Google Scholar 

  210. 210

    Division of STD Prevention et al. Sexually Transmitted Diseases Surveillance 2015. Centers for Disease Control and Prevention (2015).

  211. 211

    Ropper, A. H. Two centuries of neurology and psychiatry in the journal. N. Engl. J. Med. 367, 58–65 (2012).

    Google Scholar 

  212. 212

    Oliver, S. E. et al. Ocular syphilis — eight jurisdictions, United States, 2014–2015. MMWR. Morb. Mortal. Wkly. Rep. 65, 1185–1188 (2016).

    Google Scholar 

  213. 213

    Moradi, A. et al. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am. J. Ophthalmol. 159, 334–343.e1 (2015).

    Google Scholar 

  214. 214

    Andreyev, S. V., Setko, N. P. & Voronina, L. G. Assessment of quality of life of patients with syphilis. Prakt. Med. Infect. Dis. 7, 1 (2014).

    Google Scholar 

  215. 215

    Ferreira, A., Young, T., Mathews, C., Zunza, M. & Low, N. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst. Rev. 3, CD002843 (2013).

  216. 216

    Rzepa, T., Jakubowicz, O., Witmanowski, H. & Zaba, R. Disease-induced level of shame in patients with acne, psoriasis and syphilis. Postepy Dermatol. Alergol. 30, 233–236 (2013).

    Google Scholar 

  217. 217

    Wu, D. & Hawkes, S. Eliminating mother-to-child transmission of syphilis: the need for more consistent political commitment. J. Publ. Health Emerg. 1, 41 (2016).

    Google Scholar 

  218. 218

    Burden, C. et al. From grief, guilt pain and stigma to hope and pride — a systematic review and meta-analysis of mixed-method research of the psychosocial impact of stillbirth. BMC Pregnancy Childbirth (2016).

  219. 219

    Heazell, A. E. P. et al. Stillbirths: economic and psychosocial consequences. Lancet 387, 604–616 (2016).

    Google Scholar 

  220. 220

    Kiguli, J. et al. Stillbirths in sub-Saharan Africa: unspoken grief. Lancet 387, e16–e18 (2016).

    Google Scholar 

  221. 221

    Fitzgerald, D. W. & Behets, F. M. A piece of my mind. Beyond folklore. JAMA 288, 2791–2792 (2002).

    Google Scholar 

  222. 222

    Meheus, A. & Antal, G. M. The endemic treponematoses: not yet eradicated. World Health Stat. Q. 45, 228–237 (1992).

    Google Scholar 

  223. 223

    Taylor, M. M. et al. Estimating benzathine penicillin need for the treatment of pregnant women diagnosed with syphilis during antenatal care in high-morbidity countries. PLoS ONE 11, e0159483 (2016).

    Google Scholar 

  224. 224

    Peeling, R. W. & Mabey, D. Celebrating the decline in syphilis in pregnancy: a sobering reminder of what's left to do. Lancet. Glob. Health 4, e503–e504 (2016).

    Google Scholar 

  225. 225

    World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. >WHO (2014).

  226. 226

    World Health Organization. WHO information note on the use of dual HIV/Syphilis rapid diagnostic tests (RDT). WHO (2017).

  227. 227

    Wedderburn, C. J., Murtagh, M., Toskin, I. & Peeling, R. W. Using electronic readers to monitor progress toward elimination of mother-to-child transmission of HIV and syphilis: an opinion piece. Int. J. Gynecol. Obstet. 130, S81–S83 (2015).

    Google Scholar 

  228. 228

    Guo, T., Patnaik, R., Kuhlmann, K., Rai, A. J. & Sia, S. K. Smartphone dongle for simultaneous measurement of hemoglobin concentration and detection of HIV antibodies. Lab Chip 15, 3514–3520 (2015).

    Google Scholar 

  229. 229

    Peeling, R. W. Diagnostics in a digital age: an opportunity to strengthen health systems and improve health outcomes. Int. Health 7, 384–389 (2015).

    Google Scholar 

  230. 230

    Hook, E. W. Syphilis. Lancet 389, 1550–1557 (2017).

    Google Scholar 

  231. 231

    Lewnard, J. A. & Berrang-Ford, L. Internet-based partner selection and risk for unprotected anal intercourse in sexual encounters among men who have sex with men: a meta-analysis of observational studies. Sex. Transm. Infect. 90, 290–296 (2014).

    Google Scholar 

  232. 232

    Tuddenham, S., Shah, M. & Ghanem, K. G. Syphilis and HIV: is HAART at the heart of this epidemic? Sex. Transm. Infect. 93, 311–312 (2017).

    Google Scholar 

  233. 233

    Ho, E. L., Tantalo, L. C., Jones, T., Sahi, S. K. & Marra, C. M. Point-of-care treponemal tests for neurosyphilis diagnosis. Sex. Transm. Dis. 42, 48–52 (2015).

    Google Scholar 

  234. 234

    Lin, L.-R. et al. Macrophage migration inhibitory factor as a novel cerebrospinal fluid marker for neurosyphilis among HIV-negative patients. Clin. Chim. Acta 463, 103–108 (2016).

    Google Scholar 

  235. 235

    Marra, C. M., Tantalo, L. C., Sahi, S. K., Maxwell, C. L. & Lukehart, S. A. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex. Transm. Dis. 37, 283–287 (2010).

    Google Scholar 

  236. 236

    Cameron, C. E. & Lukehart, S. A. Current status of syphilis vaccine development: need, challenges, prospects. Vaccine 32, 1602–1609 (2014). This review described the progress in vaccine development for syphilis and all the challenges that need to be overcome.

    Google Scholar 

  237. 237

    Miller, J. N. Immunity in experimental syphilis. VI. Successful vaccination of rabbits with Treponema pallidum, Nichols strain, attenuated by -irradiation. J. Immunol. 110, 1206–1215 (1973).

    Google Scholar 

  238. 238

    Arora, N. et al. Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster. Nat. Microbiol. 2, 16245 (2016).

    Google Scholar 

  239. 239

    Izard, J. et al. Cryo-electron tomography elucidates the molecular architecture of Treponema pallidum, the syphilis spirochete. J. Bacteriol. 191, 7566–7580 (2009).

    Google Scholar 

  240. 240

    Liu, J. et al. Cellular architecture of Treponema pallidum: novel flagellum, periplasmic cone, and cell envelope as revealed by cryo electron tomography. J. Mol. Biol. 403, 546–561 (2010).

    Google Scholar 

  241. 241

    Brautigam, C. A., Deka, R. K., Liu, W. Z. & Norgard, M. V. Insights into the potential function and membrane organization of the TP0435 (Tp17) lipoprotein fromTreponema pallidum derived from structural and biophysical analyses. Protein Sci. 24, 11–19 (2014).

    Google Scholar 

  242. 242

    Erkens, G. B., Majsnerowska, M., ter Beek, J. & Slotboom, D. J. Energy coupling factor-type ABC transporters for vitamin uptake in prokaryotes. Biochemistry 51, 4390–4396 (2012).

    Google Scholar 

  243. 243

    Boudker, O., Ryan, R. M., Yernool, D., Shimamoto, K. & Gouaux, E. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 445, 387–393 (2007).

    Google Scholar 

  244. 244

    Brautigam, C. A., Deka, R. K., Schuck, P., Tomchick, D. R. & Norgard, M. V. Structural and thermodynamic characterization of the interaction between two periplasmic Treponema pallidum lipoproteins that are components of a TPR-protein-associated TRAP transporter (TPAT). J. Mol. Biol. 420, 70–86 (2012).

    Google Scholar 

  245. 245

    Deka, R. K. et al. Structural, bioinformatic, and in vivo analyses of two Treponema pallidum lipoproteins reveal a unique TRAP transporter. J. Mol. Biol. 416, 678–696 (2012).

    Google Scholar 

  246. 246

    Park, I. U. et al. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J. Infect. Dis. 204, 1297–1304 (2011).

    Google Scholar 

  247. 247

    Binnicker, M. J., Yao, J. D. & Cockerill, F. R. Non-treponemal serologic tests: a supplemental, not confirmatory testing approach. Clin. Infect. Dis. 52, 274–275 (2010).

    Google Scholar 

  248. 248

    Lipinsky, D., Schreiber, L., Kopel, V. & Shainberg, B. Validation of reverse sequence screening for syphilis. J. Clin. Microbiol. 50, 1501 (2012).

    Google Scholar 

  249. 249

    Tong, M.-L. et al. Analysis of 3 algorithms for syphilis serodiagnosis and implications for clinical management. Clin. Infect. Dis. 58, 1116–1124 (2014).

    Google Scholar 

  250. 250

    Tucker, J. D. et al. Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect. Dis. 10, 381–386 (2010).

    Google Scholar 

  251. 251

    Jafari, Y. et al. Are Treponema pallidum specific rapid and point-of-care tests for syphilis accurate enough for screening in resource limited settings? Evidence from a meta-analysis. PLoS ONE 8, e54695 (2013).

    Google Scholar 

  252. 252

    World Health Organization. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. WHO (2013).

Download references


The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

Author information




Introduction (R.W.P. and D.M.); Epidemiology (D.M. and X.-S.C.); Mechanisms/pathophysiology (J.D.R.); Diagnosis, screening and prevention (R.W.P., M.L.K., X.-S.C. and A.S.B.); Management (D.M.); Quality of life (M.K. and A.S.B.); Outlook (all authors); overview of the Primer (R.W.P.).

Corresponding author

Correspondence to Rosanna W. Peeling.

Ethics declarations

Competing interests

J.D.R. receives royalties for licensing of syphilis diagnostics reagents. The other authors declare no competing interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peeling, R., Mabey, D., Kamb, M. et al. Syphilis. Nat Rev Dis Primers 3, 17073 (2017).

Download citation

Further reading


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing